



(51) International Patent Classification:  
C07K 16/32 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:  
PCT/US2018/018768

(22) International Filing Date:  
20 February 2018 (20.02.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
62/461,145 20 February 2017 (20.02.2017) US

(71) Applicant: ADIMAB, LLC [US/US]; 7 Lucent Drive,  
Lebanon, NH 03766 (US).

(72) Inventors: CHANG, Gregory, P.; 143 Saunders Street,  
Medford, MA 02155 (US). CHEUNG, Ann, F.; 25 Morn-  
ingside Lane, Lincoln, MA 01773 (US). HANEY, William;  
61 Lincoln Road, Wayland, MA 01778 (US). LUNDE,  
Bradley, M.; 7 Lucent Drive, Lebanon, NH 03766 (US).  
PRINZ, Bianka; 7 Lucent Drive, Lebanon, NH 03766  
(US).

(74) Agent: ASHRAF, Shovon et al.; Goodwin Procter LLP,  
100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PROTEINS BINDING CD33, NKG2D AND CD16

FIG. 1



(57) Abstract: Multi-specific binding proteins that bind CD33, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.



**PROTEINS BINDING CD33, NKG2D AND CD16**

## CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62/461,145, filed February 20, 2017, the entire contents of which are  
5 incorporated by reference herein for all purposes.

## SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on February 19, 2018, is named DFY-007PC\_SL.txt and is 98,304 bytes  
10 in size.

## FIELD OF THE INVENTION

[0003] The invention relates to multi-specific binding proteins that bind to CD33, the NKG2D receptor, and CD16.

## BACKGROUND

15 [0004] Cancer continues to be a significant health problem despite the substantial research efforts and scientific advances reported in the literature for treating this disease. Some of the most frequently diagnosed cancers in adults include prostate cancer, breast cancer, and lung cancer. Hematological malignancies, though less frequent than solid cancers, have low survival rates. Current treatment options for these cancers are not effective  
20 for all patients and/or can have substantial adverse side effects. Other types of cancer also remain challenging to treat using existing therapeutic options.

[0005] Cancer immunotherapies are desirable because they are highly specific and can facilitate destruction of cancer cells using the patient's own immune system. Fusion proteins such as bi-specific T-cell engagers are cancer immunotherapies described in the literature that  
25 bind to tumor cells and T-cells to facilitate destruction of tumor cells. Antibodies that bind to certain tumor-associated antigens and to certain immune cells have been described in the literature. *See, e.g.*, WO 2016/134371 and WO 2015/095412.

[0006] Natural killer (NK) cells are a component of the innate immune system and make up approximately 15% of circulating lymphocytes. NK cells infiltrate virtually all tissues and  
30 were originally characterized by their ability to kill tumor cells effectively without the need

for prior sensitization. Activated NK cells kill target cells by means similar to cytotoxic T cells – i.e. via cytolytic granules that contain perforin and granzymes as well as via death receptor pathways. Activated NK cells also secrete inflammatory cytokines such as IFN-gamma and chemokines that promote the recruitment of other leukocytes to the target tissue.

5 [0007] NK cells respond to signals through a variety of activating and inhibitory receptors on their surface. For example, when NK cells encounter healthy self-cells, their activity is inhibited through activation of the killer-cell immunoglobulin-like receptors (KIRs). Alternatively, when NK cells encounter foreign cells or cancer cells, they are activated via their activating receptors (*e.g.* NKG2D, NCRs, DNAM1). NK cells are also  
10 activated by the constant region of some immunoglobulins through CD16 receptors on their surface. The overall sensitivity of NK cells to activation depends on the sum of stimulatory and inhibitory signals.

[0008] CD33 is a member of the sialic acid-binding immunoglobulin-like lectins. As a transmembrane receptor mainly expressed on cells of myeloid lineage, CD33 modulates  
15 inflammatory and immune responses through a dampening effect on tyrosine kinase-driven signaling pathways. For example, CD33 was shown to constitutively suppress the production of pro-inflammatory cytokines such as IL-1 $\beta$ , TNF- $\alpha$ , and IL-8 by human monocytes.

[0009] CD33 is associated with hematopoietic cancers. It is broadly expressed in blasts of nearly all acute myeloid leukemia (AML). Furthermore, hematopoietic cancer stem and/or  
20 progenitor cells are found to be CD33<sup>+</sup>, implying that CD33-directed therapy could potentially eradicate malignant stem and/or progenitor cells in such cases while sparing normal hematopoietic stem cells. In addition to its expression in AML, CD33 is found on other myeloid neoplasms (*e.g.* myelodysplastic syndromes and myeloproliferative neoplasms) and on subsets of B-cell and T-cell acute lymphoblastic leukemias (ALL)/lymphoblastic  
25 lymphomas. This expression pattern has led to the use of CD33-directed therapeutics in patients with malignancies including AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, and ALLs.

## SUMMARY

[0010] The invention provides multi-specific binding proteins that bind to CD33 on a  
30 cancer cell and to the NKG2D receptor and CD16 receptor on natural killer cells. Such proteins can engage more than one kind of NK activating receptor, and may block the binding of natural ligands to NKG2D. In certain embodiments, the proteins can agonize NK cells in

humans, and in other species such as rodents and cynomolgus monkeys. Various aspects and embodiments of the invention are described in further detail below.

[0011] Accordingly, one aspect of the invention provides a protein that incorporates a first antigen-binding site that binds NKG2D; a second antigen-binding site that binds to  
5 CD33; and an antibody Fc domain, a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16. The antigen-binding sites may each incorporate an antibody heavy chain variable domain and an antibody light chain variable domain, *e.g.*, arranged as in an antibody, or fused together to form an scFv, or one or more of the antigen-binding sites may be a single domain antibody, such as a V<sub>H</sub>H antibody like a camelid  
10 antibody or a V<sub>NAR</sub> antibody like those found in cartilaginous fish.

[0012] The first antigen-binding site, which binds to NKG2D, in one embodiment, can incorporate a heavy chain variable domain related to SEQ ID NO:1, such as by having an amino acid sequence at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:1, and/or incorporating amino acid sequences  
15 identical to the CDR1 (SEQ ID NO:54), CDR2 (SEQ ID NO:55), and CDR3 (SEQ ID NO:56) sequences of SEQ ID NO:1. Alternatively, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:41 and a light chain variable domain related to SEQ ID NO:42. For example, the heavy chain variable domain of the first antigen binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%,  
20 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:41, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:57), CDR2 (SEQ ID NO:58), and CDR3 (SEQ ID NO:59) sequences of SEQ ID NO:41. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:42, and/or incorporate amino acid  
25 sequences identical to the CDR1 (SEQ ID NO:60), CDR2 (SEQ ID NO:61), and CDR3 (SEQ ID NO:62) sequences of SEQ ID NO:42. In other embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:43 and a light chain variable domain related to SEQ ID NO:44. For example, the heavy chain variable domain of the first antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%,  
30 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:43, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:63), CDR2 (SEQ ID NO:64), and CDR3 (SEQ ID NO:65) sequences of SEQ ID NO:43. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:44, and/or incorporate amino acid

sequences identical to the CDR1 (SEQ ID NO:66), CDR2 (SEQ ID NO:67), and CDR3 (SEQ ID NO:68) sequences of SEQ ID NO:44.

**[0013]** In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:45 and a light chain variable domain related to SEQ ID NO:46, such as by having amino acid sequences at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:45 and at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:46 respectively. In another embodiment, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:47 and a light chain variable domain related to SEQ ID NO:48, such as by having amino acid sequences at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:47 and at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:48 respectively.

**[0014]** In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:69 and a light chain variable domain related to SEQ ID NO:70. For example, the heavy chain variable domain of the first antigen binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:69, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:71), CDR2 (SEQ ID NO:72), and CDR3 (SEQ ID NO:73) sequences of SEQ ID NO:69. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:70, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:74), CDR2 (SEQ ID NO:75), and CDR3 (SEQ ID NO:76) sequences of SEQ ID NO:70. In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:77 and a light chain variable domain related to SEQ ID NO:78. For example, the heavy chain variable domain of the first antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:77, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:69), CDR2 (SEQ ID NO:80), and CDR3 (SEQ ID NO:81) sequences of SEQ ID NO:77. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:78, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:82), CDR2 (SEQ ID NO:83), and CDR3 (SEQ ID NO:84) sequences of SEQ ID NO:78.

[0015] In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:85 and a light chain variable domain related to SEQ ID NO:86. For example, the heavy chain variable domain of the first antigen binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:85, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:87), CDR2 (SEQ ID NO:88), and CDR3 (SEQ ID NO:89) sequences of SEQ ID NO:85. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:86, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:90), CDR2 (SEQ ID NO:91), and CDR3 (SEQ ID NO:92) sequences of SEQ ID NO:86.

[0016] In some embodiments, the first antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:133 and a light chain variable domain related to SEQ ID NO:134. For example, the heavy chain variable domain of the first antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:133, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:135), CDR2 (SEQ ID NO:136), and CDR3 (SEQ ID NO:137) sequences of SEQ ID NO:133. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:134, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:138), CDR2 (SEQ ID NO:139), and CDR3 (SEQ ID NO:140) sequences of SEQ ID NO:134.

[0017] The second antigen-binding site can optionally incorporate a heavy chain variable domain related to SEQ ID NO:93 and a light chain variable domain related to SEQ ID NO:94. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:93, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:95), CDR2 (SEQ ID NO:96), and CDR3 (SEQ ID NO:97) sequences of SEQ ID NO:93. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:94 and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:98), CDR2 (SEQ ID NO:99), and CDR3 (SEQ ID NO:100) sequences of SEQ ID NO:94.

**[0018]** Alternatively, the second antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:101 and a light chain variable domain related to SEQ ID NO:102. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:101, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:103), CDR2 (SEQ ID NO:104), and CDR3 (SEQ ID NO:105) sequences of SEQ ID NO:101. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:58, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:106), CDR2 (SEQ ID NO:107), and CDR3 (SEQ ID NO:108) sequences of SEQ ID NO:102.

**[0019]** In another embodiment, the second antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:109 and a light chain variable domain related to SEQ ID NO:110. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:59, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:111), CDR2 (SEQ ID NO:112), and CDR3 (SEQ ID NO:113) sequences of SEQ ID NO:109. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:110, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:114), CDR2 (SEQ ID NO:115), and CDR3 (SEQ ID NO:116) sequences of SEQ ID NO:110.

**[0020]** In another embodiment, the second antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:117 and a light chain variable domain related to SEQ ID NO:118. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:117, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:119), CDR2 (SEQ ID NO:120), and CDR3 (SEQ ID NO:121) sequences of SEQ ID NO:117. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO:118, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:122), CDR2 (SEQ ID NO:123), and CDR3 (SEQ ID NO:124) sequences of SEQ ID NO:118.

[0021] In another embodiment, the second antigen-binding site can incorporate a heavy chain variable domain related to SEQ ID NO:125 and a light chain variable domain related to SEQ ID NO:126. For example, the heavy chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,  
5 99%, or 100%) identical to SEQ ID NO:125, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:127), CDR2 (SEQ ID NO:128), and CDR3 (SEQ ID NO:129) sequences of SEQ ID NO:125. Similarly, the light chain variable domain of the second antigen-binding site can be at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%,  
10 97%, 98%, 99%, or 100%) identical to SEQ ID NO:126, and/or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:130), CDR2 (SEQ ID NO:131), and CDR3 (SEQ ID NO:132) sequences of SEQ ID NO:126.

[0022] In some embodiments, the second antigen-binding site incorporates a light chain variable domain having an amino acid sequence identical to the amino acid sequence of the light chain variable domain present in the first antigen-binding site.

15 [0023] In some embodiments, the protein incorporates a portion of an antibody Fc domain sufficient to bind CD16, wherein the antibody Fc domain comprises hinge and CH2 domains, and/or amino acid sequences at least 90% identical to amino acid sequence 234-332 of a human IgG antibody.

[0024] Formulations containing one of these proteins; cells containing one or more  
20 nucleic acids expressing these proteins, and methods of enhancing tumor cell death using these proteins are also provided.

[0025] Another aspect of the invention provides a method of treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of the multi-specific binding protein described herein. Exemplary cancers for  
25 treatment using the multi-specific binding proteins include, for example, wherein the cancer is selected from the group consisting of AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, and ALLs.

#### BRIEF DESCRIPTION OF THE DRAWINGS

[0026] **FIG. 1** is a representation of a heterodimeric, multi-specific antibody. Each arm  
30 can represent either the NKG2D-binding domain or CD33-binding domain. In some embodiments, the NKG2D- and CD33-binding domains can share a common light chain.



- [0027] FIG. 2 is a representation of a heterodimeric, multi-specific antibody. Either the NKG2D- or CD33-binding domain can take the scFv format (right arm).
- [0028] FIG. 3 are line graphs demonstrating the binding affinity of NKG2D-binding domains (listed as clones) to human recombinant NKG2D in an ELISA assay.
- 5 [0029] FIG. 4 are line graphs demonstrating the binding affinity of NKG2D-binding domains (listed as clones) to cynomolgus recombinant NKG2D in an ELISA assay.
- [0030] FIG. 5 are line graphs demonstrating the binding affinity of NKG2D-binding domains (listed as clones) to mouse recombinant NKG2D in an ELISA assay.
- [0031] FIG. 6 are bar graphs demonstrating the binding of NKG2D-binding domains  
10 (listed as clones) to EL4 cells expressing human NKG2D by flow cytometry showing mean fluorescence intensity (MFI) fold over background.
- [0032] FIG. 7 are bar graphs demonstrating the binding of NKG2D-binding domains (listed as clones) to EL4 cells expressing mouse NKG2D by flow cytometry showing mean fluorescence intensity (MFI) fold over background.
- 15 [0033] FIG. 8 are line graphs demonstrating specific binding affinity of NKG2D-binding domains (listed as clones) to recombinant human NKG2D-Fc by competing with natural ligand ULBP-6.
- [0034] FIG. 9 are line graphs demonstrating specific binding affinity of NKG2D-binding domains (listed as clones) to recombinant human NKG2D-Fc by competing with natural  
20 ligand MICA.
- [0035] FIG. 10 are line graphs demonstrating specific binding affinity of NKG2D-binding domains (listed as clones) to recombinant mouse NKG2D-Fc by competing with natural ligand Rae-1 delta.
- [0036] FIG. 11 are bar graphs showing activation of human NKG2D by NKG2D-binding  
25 domains (listed as clones) by quantifying the percentage of TNF-alpha positive cells, which express human NKG2D-CD3 zeta fusion proteins.
- [0037] FIG. 12 are bar graphs showing activation of mouse NKG2D by NKG2D-binding domains (listed as clones) by quantifying the percentage of TNF-alpha positive cells, which express mouse NKG2D-CD3 zeta fusion proteins.
- 30 [0038] FIG. 13 are bar graphs showing activation of human NK cells by NKG2D-binding domains (listed as clones).
- [0039] FIG. 14 are bar graphs showing activation of human NK cells by NKG2D-binding domains (listed as clones).

[0040] FIG. 15 are bar graphs showing activation of mouse NK cells by NKG2D-binding domains (listed as clones).

[0041] FIG. 16 are bar graphs showing activation of mouse NK cells by NKG2D-binding domains (listed as clones).

5 [0042] FIG. 17 are bar graphs showing the cytotoxic effect of NKG2D-binding domains (listed as clones) on tumor cells.

[0043] FIG. 18 are bar graphs showing the melting temperature of NKG2D-binding domains (listed as clones) measured by differential scanning fluorimetry.

[0044] FIGs. 19A-19C are bar graphs of synergistic activation of NK cells using CD16 and NKG2D binding. FIG. 19A demonstrates levels of CD107a; FIG. 19B demonstrates levels of IFN $\gamma$ ; FIG. 19C demonstrates levels of CD107a and IFN $\gamma$ . Graphs indicate the mean (n = 2)  $\pm$ SD. Data are representative of five independent experiments using five different healthy donors.

[0045] FIG. 20 is a representation of a TriNKET in the Triomab form, which is a trifunctional, bispecific antibody that maintains an IgG-like shape. This chimera consists of two half antibodies, each with one light and one heavy chain, that originate from two parental antibodies. Triomab form may be an heterodimeric construct containing  $\frac{1}{2}$  of rat antibody and  $\frac{1}{2}$  of mouse antibody.

[0046] FIG. 21 is a representation of a TriNKET in the KiH Common Light Chain (LC) form, which involves the knobs-into-holes (KIHS) technology. KiH is a heterodimer containing 2 Fabs binding to target 1 and 2, and an Fc stabilized by heterodimerization mutations. TriNKET in the KiH format may be an heterodimeric construct with 2 fabs binding to target 1 and target 2, containing two different heavy chains and a common light chain that pairs with both heavy chains.

25 [0047] FIG. 22 is a representation of a TriNKET in the dual-variable domain immunoglobulin (DVD-Ig<sup>TM</sup>) form, which combines the target binding domains of two monoclonal antibodies via flexible naturally occurring linkers, and yields a tetravalent IgG-like molecule. DVD-Ig<sup>TM</sup> is an homodimeric construct where variable domain targeting antigen 2 is fused to the N terminus of variable domain of Fab targeting antigen 1 Construct contains normal Fc.

[0048] FIG. 23 is a representation of a TriNKET in the Orthogonal Fab interface (Ortho-Fab) form, which is an heterodimeric construct that contains 2 Fabs binding to target1 and target 2 fused to Fc. LC-HC pairing is ensured by orthogonal interface. Heterodimerization is ensured by mutations in the Fc.

[0049] FIG. 24 is a representation of a TrinKET in the 2-in-1 Ig format.

[0050] FIG. 25 is a representation of a TriNKET in the ES form, which is an heterodimeric construct containing two different Fabs binding to target 1 and target 2 fused to the Fc. Heterodimerization is ensured by electrostatic steering mutations in the Fc.

5 [0051] FIG. 26 is a representation of a TriNKET in the Fab Arm Exchange form: antibodies that exchange Fab arms by swapping a heavy chain and attached light chain (half-molecule) with a heavy-light chain pair from another molecule, resulting in bispecific antibodies. Fab Arm Exchange form (cFae) is a heterodimer containing 2 Fabs binding to target 1 and 2, and an Fc stabilized by heterodimerization mutations.

10 [0052] FIG. 27 is a representation of a TriNKET in the SEED Body form, which is an heterodimer containing 2 Fabs binding to target 1 and 2, and an Fc stabilized by heterodimerization mutations.

[0053] FIG. 28 is a representation of a TriNKET in the LuZ-Y form, in which leucine zipper is used to induce heterodimerization of two different HCs. LuZ-Y form is a  
15 heterodimer containing two different scFabs binding to target 1 and 2, fused to Fc. Heterodimerization is ensured through leucine zipper motifs fused to C-terminus of Fc.

[0054] FIG. 29 is a representation of a TriNKET in the Cov-X-Body form.

[0055] FIGs. 30A-30B are representations of TriNKETs in the  $\kappa\lambda$ -Body forms, which are an heterodimeric constructs with two different Fabs fused to Fc stabilized by  
20 heterodimerization mutations: Fab1 targeting antigen 1 contains kappa LC, while second Fab targeting antigen 2 contains lambda LC. FIG. 30A is an exemplary representation of one form of a  $\kappa\lambda$ -Body; FIG. 30B is an exemplary representation of another  $\kappa\lambda$ -Body.

[0056] FIG. 31 is an Oasc-Fab heterodimeric construct that includes Fab binding to target 1 and scFab binding to target 2 fused to Fc. Heterodimerization is ensured by mutations  
25 in the Fc.

[0057] FIG. 32 is a DuetMab, which is an heterodimeric construct containing two different Fabs binding to antigens 1 and 2, and Fc stabilized by heterodimerization mutations. Fab 1 and 2 contain differential S-S bridges that ensure correct light chain (LC) and heavy chain (HC) pairing.

30 [0058] FIG. 33 is a CrossmAb, which is an heterodimeric construct with two different Fabs binding to targets 1 and 2 fused to Fc stabilized by heterodimerization. CL and CH1 domains and VH and VL domains are switched, *e.g.*, CH1 is fused in-line with VL, while CL is fused in-line with VH.

[0059] FIG. 34 is a Fit-Ig, which is an homodimeric constructs where Fab binding to antigen 2 is fused to the N terminus of HC of Fab that binds to antigen 1. The construct contains wild-type Fc.

[0060] FIGS. 35A-35B are binding profiles of CD33-targeting TriNKETs to NKG2D expressed on EL4 cells. FIG. 35A shows binding of the TriNKETs in comparison with the monoclonal antibodies which contain the corresponding NKG2D binding domain. FIG. 35B shows the binding profile of CD33-targeting TriNKETs which include 6 different NKG2D binding domains.

[0061] FIGS. 36A and 36B are binding profiles of CD33-targeting TriNKETs to CD33 expressed on MV4-11 human AML cells. FIG. 36C is a binding profile of CD33-targeting TriNKETs and CD33 monoclonal antibody to CD33 expressed on Molm-13 human AML cells. FIG. 36D is binding profile of CD33-targeting TriNKETs and CD33 monoclonal antibody to CD33 expressed on human AML cell line MV4-11.

[0062] FIGS. 37A – 37B are line graphs demonstrating TriNKET-mediated activation of rested or IL-2-activated human NK cells in co-culture with the CD33-expressing human AML cell line MV4-11. FIG. 37A shows TriNKET-mediated activation of resting human NK cells. FIG. 37B shows TriNKET-mediated activation of IL-2-activated human NK cells from the same donor. NK cells alone, NK cells co-culturing with MV4-11 cells but without TriNKETs, and a CD20-targeting TriNKET were used controls.

[0063] FIGS. 38A – 38C are histograms showing that expression of the high-affinity FcR $\gamma$ I (CD64) on three human AML cells lines, Molm-13 cell line (FIG. 38A), MV4-11 cell line (FIG. 38B), and THP-1 cell line (FIG. 38C).

[0064] FIGS. 39A - 39B are line graphs of CD33 monoclonal antibody or TriNKETs mediated activation of human NK cells in co-culture with either Molm-13 (FIG. 39B) or THP-1 (FIG. 39A) cells. FIG. 39C shows activation of human NK cells by TriNKETs in co-culture with MV4-11 human AML cell line. HER2-TriNKET was used as a control.

[0065] FIGS. 40A – 40C are line graphs of human NK cytotoxicity towards three human AML cell lines mediated by CD33-targeting TriNKETs and the corresponding CD33 monoclonal antibody. FIG. 40A shows that CD33 monoclonal antibody showed reduced efficacy towards MV4-11 cells, which express CD64, but at a lower level than THP-1. FIG. 40B demonstrates that CD33 monoclonal antibody showed good efficacy towards Molm-13 cells, which do not express CD64. FIG. 40C demonstrates that CD33 monoclonal antibody showed no effect on THP-1 cells.

[0066] FIG. 41 shows TriNKETs-mediated cytotoxicity of rested human NK cells towards Molm-13 cells.

[0067] FIG. 42A is a bar graph showing that B cells from a health donor are protected from CD33-targeting TriNKET-mediated lysis. FIG. 42B is a bar graph showing that autologous CD33+ myeloid cells were protected from CD33-targeting TriNKET-mediated NK cell responses, and, therefore, were resistant to TriNKET-mediated lysis.

#### DETAILED DESCRIPTION

[0068] The invention provides multi-specific binding proteins that bind CD33 on a cancer cell and the NKG2D receptor and CD16 receptor on natural killer cells to activate the natural killer cells, pharmaceutical compositions comprising such multi-specific binding proteins, and therapeutic methods using such multi-specific proteins and pharmaceutical compositions, including for the treatment of cancer. Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section.

[0069] To facilitate an understanding of the present invention, a number of terms and phrases are defined below.

[0070] The terms "a" and "an" as used herein mean "one or more" and include the plural unless the context is inappropriate.

[0071] As used herein, the term "antigen-binding site" refers to the part of the immunoglobulin molecule that participates in antigen binding. In human antibodies, the antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains are referred to as "hypervariable regions" which are interposed between more conserved flanking stretches known as "framework regions," or "FR." Thus the term "FR" refers to amino acid sequences which are naturally found between and adjacent to hypervariable regions in immunoglobulins. In a human antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions," or "CDRs." In certain animals, such as camels and cartilaginous fish, the antigen-binding site is formed by a single

antibody chain providing a “single domain antibody.” Antigen-binding sites can exist in an intact antibody, in an antigen-binding fragment of an antibody that retains the antigen-binding surface, or in a recombinant polypeptide such as an scFv, using a peptide linker to connect the heavy chain variable domain to the light chain variable domain in a single  
5 polypeptide.

[0072] The term “tumor associated antigen” as used herein means any antigen including but not limited to a protein, glycoprotein, ganglioside, carbohydrate, lipid that is associated with cancer. Such antigen can be expressed on malignant cells or in the tumor microenvironment such as on tumor-associated blood vessels, extracellular matrix,  
10 mesenchymal stroma, or immune infiltrates.

[0073] As used herein, the terms “subject” and “patient” refer to an organism to be treated by the methods and compositions described herein. Such organisms preferably include, but are not limited to, mammals (*e.g.*, murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably include humans.

[0074] As used herein, the term “effective amount” refers to the amount of a compound (*e.g.*, a compound of the present invention) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “treating” includes any effect, *e.g.*, lessening, reducing, modulating,  
15 ameliorating or eliminating, that results in the improvement of the condition, disease,  
20 disorder, and the like, or ameliorating a symptom thereof.

[0075] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use *in vivo* or *ex vivo*.

[0076] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (*e.g.*, such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, *see, e.g.*, Martin, Remington's Pharmaceutical Sciences,  
25 15th Ed., Mack Publ. Co., Easton, PA [1975].  
30

[0077] As used herein, the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (*e.g.*, acid or base) of a compound of the present invention

which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof. As is known to those of skill in the art, "salts" of the compounds of the present invention may be derived from inorganic or organic acids and bases. Exemplary acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

**[0078]** Exemplary bases include, but are not limited to, alkali metal (*e.g.*, sodium) hydroxides, alkaline earth metal (*e.g.*, magnesium) hydroxides, ammonia, and compounds of formula  $NW_4^+$ , wherein W is  $C_{1-4}$  alkyl, and the like.

**[0079]** Exemplary salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include anions of the compounds of the present invention compounded with a suitable cation such as  $Na^+$ ,  $NH_4^+$ , and  $NW_4^+$  (wherein W is a  $C_{1-4}$  alkyl group), and the like.

**[0080]** For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

**[0081]** Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited

components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.

[0082] As a general matter, compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the  
5 previous definition of the variable controls.

## I. PROTEINS

[0083] The invention provides multi-specific binding proteins that bind CD33 on a cancer cell and the NKG2D receptor and CD16 receptor on natural killer cells to activate the natural killer cell. The multi-specific binding proteins are useful in the pharmaceutical compositions and therapeutic methods described herein. Binding of the multi-specific binding protein to the  
10 NKG2D receptor and CD16 receptor on natural killer cell enhances the activity of the natural killer cell toward destruction of a cancer cell. Binding of the multi-specific binding protein to CD33 on a cancer cell brings the cancer cell into proximity to the natural killer cell, which facilitates direct and indirect destruction of the cancer cell by the natural killer cell. Further  
15 description of exemplary multi-specific binding proteins is provided below.

[0084] The first component of the multi-specific binding proteins binds to NKG2D receptor-expressing cells, which can include but are not limited to NK cells,  $\gamma\delta$  T cells and CD8<sup>+</sup>  $\alpha\beta$  T cells. Upon NKG2D binding, the multi-specific binding proteins may block natural ligands, such as ULBP6 and MICA, from binding to NKG2D and activating  
20 NKG2D receptors.

[0085] The second component of the multi-specific binding proteins binds to CD33-expressing cells, which can include but are not limited to AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, and ALLs.

[0086] The third component for the multi-specific binding proteins binds to cells  
25 expressing CD16, a Fc receptor on the surface of leukocytes including natural killer cells, macrophages, neutrophils, eosinophils, mast cells, and follicular dendritic cells.

[0087] The multi-specific binding proteins described herein can take various formats. For example, one format is a heterodimeric, multi-specific antibody including a first  
30 immunoglobulin heavy chain, a first immunoglobulin light chain, a second immunoglobulin heavy chain and a second immunoglobulin light chain (FIG. 1). The first immunoglobulin heavy chain includes a first Fc (hinge-CH2-CH3) domain, a first heavy chain variable domain



and optionally a first CH1 heavy chain domain. The first immunoglobulin light chain includes a first light chain variable domain and a first light chain constant domain. The first immunoglobulin light chain, together with the first immunoglobulin heavy chain, forms an antigen-binding site that binds NKG2D. The second immunoglobulin heavy chain comprises  
5 a second Fc (hinge-CH2-CH3) domain, a second heavy chain variable domain and optionally a second CH1 heavy chain domain. The second immunoglobulin light chain includes a second light chain variable domain and a second light chain constant domain. The second immunoglobulin light chain, together with the second immunoglobulin heavy chain, forms an antigen-binding site that binds CD33. The first Fc domain and second Fc domain together are  
10 able to bind to CD16 (FIG. 1). In some embodiments, the first immunoglobulin light chain can be identical to the second immunoglobulin light chain.

**[0088]** Another exemplary format involves a heterodimeric, multi-specific antibody including a first immunoglobulin heavy chain, a second immunoglobulin heavy chain and an immunoglobulin light chain (FIG. 2). The first immunoglobulin heavy chain includes a first  
15 Fc (hinge-CH2-CH3) domain fused via either a linker or an antibody hinge to a single-chain variable fragment (scFv) composed of a heavy variable domain and light chain variable domain which pair and bind NKG2D or CD33. The second immunoglobulin heavy chain includes a second Fc (hinge-CH2-CH3) domain, a second heavy chain variable domain and optionally a CH1 heavy chain domain. The immunoglobulin light chain includes a light chain  
20 variable domain and a constant light chain domain. The second immunoglobulin heavy chain pairs with the immunoglobulin light chain and binds to NKG2D or CD33. The first Fc domain and the second Fc domain together are able to bind to CD16 (FIG. 2).

**[0089]** One or more additional binding motifs may be fused to the C-terminus of the constant region CH3 domain, optionally via a linker sequence. In certain embodiments, the  
25 antigen-binding site could be a single-chain or disulfide-stabilized variable region (scFv) or could form a tetravalent or trivalent molecule.

**[0090]** In some embodiments, the multi-specific binding protein is in the Triomab form, which is a trifunctional, bispecific antibody that maintains an IgG-like shape. This chimera consists of two half antibodies, each with one light and one heavy chain, that originate from  
30 two parental antibodies.

**[0091]** In some embodiments, the multi-specific binding protein is the KiH Common Light Chain (LC) form, which involves the knobs-into-holes (KIHS) technology. The KIHS

involves engineering C<sub>H3</sub> domains to create either a “knob” or a “hole” in each heavy chain to promote heterodimerization. The concept behind the “Knobs-into-Holes (KiH)” Fc technology was to introduce a “knob” in one CH<sub>3</sub> domain (CH<sub>3A</sub>) by substitution of a small residue with a bulky one (*e.g.*, T366W<sub>CH<sub>3A</sub></sub> in EU numbering). To accommodate the “knob,” a complementary “hole” surface was created on the other CH<sub>3</sub> domain (CH<sub>3B</sub>) by replacing the closest neighboring residues to the knob with smaller ones (*e.g.*, T366S/L368A/Y407V<sub>CH<sub>3B</sub></sub>). The “hole” mutation was optimized by structured-guided phage library screening (Atwell S, Ridgway JB, Wells JA, Carter P., Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library, *J. Mol. Biol.* (1997) 270(1):26–35). X-ray crystal structures of KiH Fc variants (Elliott JM, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, *et al.*, Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH<sub>2</sub>-CH<sub>3</sub> hydrophobic interaction. *J. Mol. Biol.* (2014) 426(9):1947–57; Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for Fcγ<sub>1</sub>R. *Mol. Immunol.* (2014) 58(1):132–8) demonstrated that heterodimerization is thermodynamically favored by hydrophobic interactions driven by steric complementarity at the inter-CH<sub>3</sub> domain core interface, whereas the knob–knob and the hole–hole interfaces do not favor homodimerization owing to steric hindrance and disruption of the favorable interactions, respectively.

20 [0092] In some embodiments, the multi-specific binding protein is in the dual-variable domain immunoglobulin (DVD-Ig<sup>TM</sup>) form, which combines the target binding domains of two monoclonal antibodies via flexible naturally occurring linkers, and yields a tetravalent IgG-like molecule.

25 [0093] In some embodiments, the multi-specific binding protein is in the Orthogonal Fab interface (Ortho-Fab) form. In the ortho-Fab IgG approach (Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, *et al.*, Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. *Nat. Biotechnol.* (2014) 32(2):191–8), structure-based regional design introduces complementary mutations at the LC and HC<sub>VH-CH1</sub> interface in only one Fab, without any changes being made to the other Fab.

30 [0094] In some embodiments, the multi-specific binding protein is in the 2-in-1 Ig format. In some embodiments, the multi-specific binding protein is in the ES form, which is a heterodimeric construct containing two different Fabs binding to targets 1 and target 2 fused to the Fc. Heterodimerization is ensured by electrostatic steering mutations in the Fc. In some

embodiments, the multi-specific binding protein is in the  $\kappa\lambda$ -Body form, which is an heterodimeric constructs with two different Fabs fused to Fc stabilized by heterodimerization mutations: Fab1 targeting antigen 1 contains kappa LC, while second Fab targeting antigen 2 contains lambda LC. FIG. 30A is an exemplary representation of one form of a  $\kappa\lambda$ -Body;  
5 FIG. 30B is an exemplary representation of another  $\kappa\lambda$ -Body.

[0095] In some embodiments, the multi-specific binding protein is in Fab Arm Exchange form (antibodies that exchange Fab arms by swapping a heavy chain and attached light chain (half-molecule) with a heavy-light chain pair from another molecule, which results in bispecific antibodies). In some embodiments, the multi-specific binding protein is in the  
10 SEED Body form. The strand-exchange engineered domain (SEED) platform was designed to generate asymmetric and bispecific antibody-like molecules, a capability that expands therapeutic applications of natural antibodies. This protein engineered platform is based on exchanging structurally related sequences of immunoglobulin within the conserved CH3 domains. The SEED design allows efficient generation of AG/GA heterodimers, while  
15 disfavoring homodimerization of AG and GA SEED CH3 domains. (Muda M. *et al.*, *Protein Eng. Des. Sel.* (2011, 24(5):447-54)). In some embodiments, the multi-specific binding protein is in the LuZ-Y form, in which a leucine zipper is used to induce heterodimerization of two different HCs. (Wranik, BJ. *et al.*, *J. Biol. Chem.* (2012), 287:43331-9).

[0096] In some embodiments, the multi-specific binding protein is in the Cov-X-Body  
20 form. In bispecific CovX-Bodies, two different peptides are joined together using a branched azetidione linker and fused to the scaffold antibody under mild conditions in a site-specific manner. Whereas the pharmacophores are responsible for functional activities, the antibody scaffold imparts long half-life and Ig-like distribution. The pharmacophores can be chemically optimized or replaced with other pharmacophores to generate optimized or unique  
25 bispecific antibodies. (Doppalapudi VR *et al.*, *PNAS* (2010), 107(52);22611-22616).

[0097] In some embodiments, the multi-specific binding protein is in an Oasc-Fab heterodimeric form that includes Fab binding to target 1, and scFab binding to target 2 fused to Fc. Heterodimerization is ensured by mutations in the Fc.

[0098] In some embodiments, the multi-specific binding protein is in a DuetMab form,  
30 which is an heterodimeric construct containing two different Fabs binding to antigens 1 and 2, and Fc stabilized by heterodimerization mutations. Fab 1 and 2 contain differential S-S bridges that ensure correct LC and HC pairing.

**[0099]** In some embodiments, the multi-specific binding protein is in a CrossmAb form, which is an heterodimeric construct with two different Fabs binding to targets 1 and 2, fused to Fc stabilized by heterodimerization. CL and CH1 domains and VH and VL domains are switched, *e.g.*, CH1 is fused in-line with VL, while CL is fused in-line with VH.

5 **[00100]** In some embodiments, the multi-specific binding protein is in a Fit-Ig form, which is an homodimeric constructs where Fab binding to antigen 2 is fused to the N terminus of HC of Fab that binds to antigen 1. The construct contains wild-type Fc.

**[00101]** Table 1 lists peptide sequences of heavy chain variable domains and light chain variable domains that, in combination, can bind to NKG2D. The NKG2D binding domains  
10 can vary in their binding affinity to NKG2D, nevertheless, they all activate human NKG2D and NK cells.

| Table 1   |   |  |
|-----------|---|--|
| Clones    | Heavy chain variable region amino acid sequence   | Light chain variable region amino acid sequence  |
| ADI-27705 | QVQLQQWGAGLLKPSETLSLTCAVY<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKS RVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPPWGQGLTVTVSS<br>(SEQ ID NO:1)<br><br>CDR1 (SEQ ID NO:54) – GSFSGYYWS<br>CDR2 (SEQ ID NO:55) –<br>EIDHSGSTNYNPSLKS<br>CDR3 (SEQ ID NO:56) –<br>ARARGPWSFDPP | DIQMTQSPSTLSASVGDRVTITCR<br>ASQSISSWLAWYQQKPGKAPKLL<br>IYKASSLESQVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYNSYPI<br>TFGGGTKVEIK<br>(SEQ ID NO:2) |
| ADI-27724 | QVQLQQWGAGLLKPSETLSLTCAVY<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKS RVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPPWGQGLTVTVSS<br>(SEQ ID NO:3)  | EIVLTQSPGTLSPGERATLSCRA<br>SQSVSSSYLAWYQQKPGQAPRLL<br>IYGASSRATGIPDRFSGSGSGTDFT<br>LTISRLEPEDFAVYYCQQYGSSPIT<br>FGGGTKVEIK<br>(SEQ ID NO:4)  |
| ADI-27740 | QVQLQQWGAGLLKPSETLSLTCAVY   | DIQMTQSPSTLSASVGDRVTITCR   |

|                    |   |   |
|--------------------|---|---|
| (A40)              | GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:5)                               | ASQSIGSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYHSFYT<br>FGGGTKVEIK<br>(SEQ ID NO:6)                               |
| ADI-27741          | QVQLQQWGAGLLKPSETLSLTCAVY<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:7)  | DIQMTQSPSTLSASVGDRVITICR<br>ASQSIGSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQSNSYYT<br>FGGGTKVEIK<br>(SEQ ID NO:8)   |
| ADI-27743          | QVQLQQWGAGLLKPSETLSLTCAVY<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:9)  | DIQMTQSPSTLSASVGDRVITICR<br>ASQSISSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYNSYPT<br>FGGGTKVEIK<br>(SEQ ID NO:10)  |
| ADI-28153          | QVQLQQWGAGLLKPSETLSLTCAVY<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>GFDPWGQGTLVTVSS<br>(SEQ ID NO:11) | ELQMTQSPSSLSASVGDRVITICR<br>TSQSISSYLNWYQQKPGQPPKLLI<br>YWASTRESGVPDRFSGSGSGTDF<br>LTISSLQPEDSATYYCQQSYDIP<br>YTFGQGTKLEIK<br>(SEQ ID NO:12)  |
| ADI-28226<br>(C26) | QVQLQQWGAGLLKPSETLSLTCAVY<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:13) | DIQMTQSPSTLSASVGDRVITICR<br>ASQSISSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYGSFPIT<br>FGGGTKVEIK<br>(SEQ ID NO:14) |
| ADI-28154          | QVQLQQWGAGLLKPSETLSLTCAVY<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW                                      | DIQMTQSPSTLSASVGDRVITICR<br>ASQSISSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTDF<br>LTISSLQPDDFATYYCQQSKEVP                                    |

|           |  |  |
|-----------|--|--|
|           | SFDPWGQGTLVTVSS<br>(SEQ ID NO:15)  | WTFGQGTKVEIK<br>(SEQ ID NO:16)   |
| ADI-29399 | QVQLQQWGAGLLKPSETLSLTCAYV<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:17) | DIQMTQSPSTLSASVGDRVITICR<br>ASQSISSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYNSFPT<br>FGGGTKVEIK<br>(SEQ ID NO:18) |
| ADI-29401 | QVQLQQWGAGLLKPSETLSLTCAYV<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:19) | DIQMTQSPSTLSASVGDRVITICR<br>ASQSIGSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYDIYPT<br>FGGGTKVEIK<br>(SEQ ID NO:20) |
| ADI-29403 | QVQLQQWGAGLLKPSETLSLTCAYV<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:21) | DIQMTQSPSTLSASVGDRVITICR<br>ASQSISSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYDSYPT<br>FGGGTKVEIK<br>(SEQ ID NO:22) |
| ADI-29405 | QVQLQQWGAGLLKPSETLSLTCAYV<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:23) | DIQMTQSPSTLSASVGDRVITICR<br>ASQSISSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYGSFPT<br>FGGGTKVEIK<br>(SEQ ID NO:24) |
| ADI-29407 | QVQLQQWGAGLLKPSETLSLTCAYV<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:25) | DIQMTQSPSTLSASVGDRVITICR<br>ASQSISSWLAWYQQKPGKAPKLL<br>IYKASSLESGVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYQSFT<br>FGGGTKVEIK<br>(SEQ ID NO:26)  |
| ADI-29419 | QVQLQQWGAGLLKPSETLSLTCAYV  | DIQMTQSPSTLSASVGDRVITICR   |

|           |   |   |
|-----------|---|---|
|           | <p>GGSFSGYYWSWIRQPPGKGLEWIGEI<br/>                 DHSGSTNYNPSLKSRTISVDTSKNQ<br/>                 FSLKLSSVTAADTAVYYCARARGPW<br/>                 SFDPWGQGTLVTVSS<br/>                 (SEQ ID NO:27)</p>  | <p>ASQSISSWLAWYQQKPGKAPKLL<br/>                 IYKASSLESGVPSRFSGSGSGTEFT<br/>                 LTISSLQPDDFATYYCQQYSSSFST<br/>                 FGGGTKVEIK<br/>                 (SEQ ID NO:28)</p>  |
| ADI-29421 | <p>QVQLQQWGAGLLKPSETLSLTCAVY<br/>                 GGSFSGYYWSWIRQPPGKGLEWIGEI<br/>                 DHSGSTNYNPSLKSRTISVDTSKNQ<br/>                 FSLKLSSVTAADTAVYYCARARGPW<br/>                 SFDPWGQGTLVTVSS<br/>                 (SEQ ID NO:29)</p> | <p>DIQMTQSPSTLSASVGDRVITICR<br/>                 ASQSISSWLAWYQQKPGKAPKLL<br/>                 IYKASSLESGVPSRFSGSGSGTEFT<br/>                 LTISSLQPDDFATYYCQQYESYST<br/>                 FGGGTKVEIK<br/>                 (SEQ ID NO:30)</p> |
| ADI-29424 | <p>QVQLQQWGAGLLKPSETLSLTCAVY<br/>                 GGSFSGYYWSWIRQPPGKGLEWIGEI<br/>                 DHSGSTNYNPSLKSRTISVDTSKNQ<br/>                 FSLKLSSVTAADTAVYYCARARGPW<br/>                 SFDPWGQGTLVTVSS<br/>                 (SEQ ID NO:31)</p> | <p>DIQMTQSPSTLSASVGDRVITICR<br/>                 ASQSISSWLAWYQQKPGKAPKLL<br/>                 IYKASSLESGVPSRFSGSGSGTEFT<br/>                 LTISSLQPDDFATYYCQQYDSFITF<br/>                 GGGTKVEIK<br/>                 (SEQ ID NO:32)</p> |
| ADI-29425 | <p>QVQLQQWGAGLLKPSETLSLTCAVY<br/>                 GGSFSGYYWSWIRQPPGKGLEWIGEI<br/>                 DHSGSTNYNPSLKSRTISVDTSKNQ<br/>                 FSLKLSSVTAADTAVYYCARARGPW<br/>                 SFDPWGQGTLVTVSS<br/>                 (SEQ ID NO:33)</p> | <p>DIQMTQSPSTLSASVGDRVITICR<br/>                 ASQSISSWLAWYQQKPGKAPKLL<br/>                 IYKASSLESGVPSRFSGSGSGTEFT<br/>                 LTISSLQPDDFATYYCQQYQSYPT<br/>                 FGGGTKVEIK<br/>                 (SEQ ID NO:34)</p> |
| ADI-29426 | <p>QVQLQQWGAGLLKPSETLSLTCAVY<br/>                 GGSFSGYYWSWIRQPPGKGLEWIGEI<br/>                 DHSGSTNYNPSLKSRTISVDTSKNQ<br/>                 FSLKLSSVTAADTAVYYCARARGPW<br/>                 SFDPWGQGTLVTVSS<br/>                 (SEQ ID NO:35)</p> | <p>DIQMTQSPSTLSASVGDRVITICR<br/>                 ASQSIGSWLAWYQQKPGKAPKLL<br/>                 IYKASSLESGVPSRFSGSGSGTEFT<br/>                 LTISSLQPDDFATYYCQQYHSFPT<br/>                 FGGGTKVEIK<br/>                 (SEQ ID NO:36)</p> |
| ADI-29429 | <p>QVQLQQWGAGLLKPSETLSLTCAVY<br/>                 GGSFSGYYWSWIRQPPGKGLEWIGEI<br/>                 DHSGSTNYNPSLKSRTISVDTSKNQ<br/>                 FSLKLSSVTAADTAVYYCARARGPW</p>  | <p>DIQMTQSPSTLSASVGDRVITICR<br/>                 ASQSIGSWLAWYQQKPGKAPKLL<br/>                 IYKASSLESGVPSRFSGSGSGTEFT<br/>                 LTISSLQPDDFATYYCQQYELYSY</p>   |

|                    |  |  |
|--------------------|--|--|
|                    | SFDPWGQGTLVTVSS<br>(SEQ ID NO:37)  | TFGGGTKVEIK<br>(SEQ ID NO:38)  |
| ADI-29447<br>(F47) | QVQLQQWGAGLLKPSETLSLTCVY<br>GGSFSGYYWSWIRQPPGKGLEWIGEI<br>DHSGSTNYNPSLKSRVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARARGPW<br>SFDPWGQGTLVTVSS<br>(SEQ ID NO:39)   | DIQMTQSPSTLSASVGDRTITCR<br>ASQSISSWLAWYQQKPGKAPKLL<br>IYKASSLESQVPSRFSGSGSGTEFT<br>LTISSLQPDDFATYYCQQYDFTIT<br>FGGGGTKVEIK<br>(SEQ ID NO:40)   |
| ADI-27727          | QVQLVQSGAEVKKPGSSVKVSKAS<br>GGTFSSYAISWVRQAPGQGLEWMGG<br>IIPFGTANYAQKFQGRVTITADESTS<br>TAYMELSSLRSEDVAVYYCARGDSSI<br>RHAYYYYGMDVWGQGTITVTVSS<br>(SEQ ID NO:41)<br><br>CDR1 (SEQ ID NO:57) –<br>GTFSSYAIS<br>CDR2 (SEQ ID NO:58) –<br>GIIPFGTANYAQKFQG<br>CDR3 (SEQ ID NO:59) –<br>ARGDSSIRHAYYYYGMDV | DIVMTQSPDSLAVSLGERATINCK<br>SSQSVLYSSNNKNYLAWYQQKP<br>GQPPKLLIYWASTRESGVPDRFSG<br>SGSGTDFTLTISSLQAEDVAVYYC<br>QQYYSTPITFGGGGTKVEIK<br>(SEQ ID NO:42)<br><br>CDR1 (SEQ ID NO:60) –<br>KSSQSVLYSSNNKNYLA<br>CDR2 (SEQ ID NO:61) –<br>WASTRES<br>CDR3 (SEQ ID NO:62) –<br>QQYYSTPIT |
| ADI-29443<br>(F43) | QLQLQESGPGLVKPSLTLCTVSG<br>GSISSSSYYWGWIRQPPGKGLEWIGSI<br>YYSGSTYYNPSLKSRVTISVDTSKNQ<br>FSLKLSSVTAADTAVYYCARGSDRF<br>HPYFDYWGQGTITVTVSS<br>(SEQ ID NO:43)<br><br>CDR1 (SEQ ID NO:63) –<br>GSISSSSYYWG<br>CDR2 (SEQ ID NO:64) –<br>SIYSGSTYYNPSLKS<br>CDR3 (SEQ ID NO:65) –<br>ARGSDRFHPYFDY          | EIVLTQSPATLSLSPGERATLSCRA<br>SQSVSRYLAWYQQKPGQAPRLLI<br>YDASNRATGIPARFSGSGSGTDF<br>LTISSLEPEDFAVYYCQQFDTWPP<br>TFGGGTKVEIK<br>(SEQ ID NO:44)<br><br>CDR1 (SEQ ID NO:66) –<br>RASQSVSRYLA<br>CDR2 (SEQ ID NO:67) –<br>DASNRAT<br>CDR3 (SEQ ID NO:68) –<br>QQFDTWPP                |



|                            |  |  |
|----------------------------|--|--|
| <p>ADI-29404<br/>(F04)</p> | <p>QVQLQQWGAGLLKPSETLSLTCAVY<br/>GGSFSGYYWSWIRQPPGKGLEWIGEI<br/>DHSGSTNYNPSLKS RVTVISVDTSKNQ<br/>FSLKLSSVTAADTAVYYCARARGPW<br/>SFDPWGQGTLVTVSS<br/>(SEQ ID NO:45)</p>  | <p>DIQMTQSPSTLSASVGD RVTITCR<br/>ASQSISSWLAWYQQKPGKAPKLL<br/>IYKASSLES GVP SRFSGSGSGTEFT<br/>LTISSLQPD DFATYYCEQYDSYPT<br/>FGGGTKVEIK<br/>(SEQ ID NO:46)</p>   |
| <p>ADI-28200</p>           | <p>QVQLVQSGAEVKKPGSSVKVSKAS<br/>GGTFSSY AISWVRQAPGQGLEWMGG<br/>IIPFGTANYA QKFQGRVTITADESTS<br/>TAYMELSSLRSED TAVYYCARRGRK<br/>ASGSFY YYYGMDVWGQGT TTVTVSS<br/>(SEQ ID NO:47)</p>   | <p>DIVMTQSPDSLAVSLGERATINCE<br/>SSQSLLNSGNQKNYLTWYQQKP<br/>GQPPKPLIYWASTRESGVPDRFSG<br/>SGSGTDFLT ISSLQAEDVAVYYC<br/>QNDYSYPYTFGQGTKLEIK<br/>(SEQ ID NO:48)</p>  |
| <p>ADI-27744<br/>(A44)</p> | <p>EVQLLES GGGLVQPGGSLRLS CAASG<br/>FTFSSY AMSWVRQAPGKGLEWVSAI<br/>SGSGGSTYYADSVKGRFTISRDN SKN<br/>TLYLQMNSLRAEDTAVYYCAKDGG<br/>YYDSGAGDYWGQGT LTVTVSS<br/>(SEQ ID NO:69)</p> <p>CDR1 (SEQ ID NO:71) - FTFSSYAMS<br/>CDR2 (SEQ ID NO:72) -<br/>AISGSGGSTYYADSVK G<br/>CDR3 (SEQ ID NO:73) -<br/>AKDGGYYDSGAGDY</p> | <p>DIQMTQSPSSVSASVGD RVTITCR<br/>ASQGIDSWLAWYQQKPGKAPKL<br/>LIYAASSLQSGVPSRFSGSGSGTD<br/>FTLTISSLQPEDFATYYCQQGVSY<br/>PRTFGGGTKVEIK<br/>(SEQ ID NO:70)</p> <p>CDR1 (SEQ ID NO:74) -<br/>RASQGIDSWLA<br/>CDR2 (SEQ ID NO:75) - AASSLQS<br/>CDR3 (SEQ ID NO:76) -<br/>QQGVSYPR T</p> |
| <p>ADI-27749<br/>(A49)</p> | <p>EVQLVES GGGLVKPGGSLRLS CAAS<br/>GFTFSSYS MNWVRQAPGKGLEWVSS<br/>ISSSSSYIYYADSVKGRFTISRDN AKN<br/>SLYLQMNSLRAEDTAVYYCARGAP<br/>MGAAAGW FDPWGQGT LTVTVSS<br/>(SEQ ID NO:77)</p> <p>CDR1 (SEQ ID NO:79) - FTFSSYS MN<br/>CDR2 (SEQ ID NO:80) -<br/>SISSSSSYIYYADSVK G</p>   | <p>DIQMTQSPSSVSASVGD RVTITCR<br/>ASQGISSWLAWYQQKPGKAPKLL<br/>IYAASSLQSGVPSRFSGSGSGTDF<br/>TLTISSLQPEDFATYYCQQGV SFP<br/>RTFGGGTKVEIK<br/>(SEQ ID NO:78)</p> <p>CDR1 (SEQ ID NO:82) -<br/>RASQGISSWLA<br/>CDR2 (SEQ ID NO:83) - AASSLQS</p>   |

|                    |   |   |
|--------------------|---|---|
|                    | CDR3 (SEQ ID NO:81) -<br>ARGAPMGAAAGWFDP  | CDR3 (SEQ ID NO:84) -<br>QQGVSPRT   |
| ADI-29463<br>(F63) | QVQLVQSGAEVKKPGASVKVSKAS<br>GYTFTGYMHVWRQAPGQGLEWM<br>GWINPNSGGTNYAQKFQGRVTMTR<br>DTSISTAYMELSRRLSDDTAVYYCAR<br>DTGEYYDTDDHGMDVWGQGTTVTV<br>SS<br>(SEQ ID NO:85)<br><br>CDR1 (SEQ ID NO:87) - YTFTGYMH<br>CDR2 (SEQ ID NO:88) -<br>WINPNSGGTNYAQKFQG<br>CDR3 (SEQ ID NO:89) -<br>ARDTGEYYDTDDHGMDV        | EIVLTQSPGTLSPGERATLSCRA<br>SQSVSSNLAWYQQKPGQAPRLLI<br>YGASTRATGIPARFSGSGSGTEFT<br>LTISSLQSEDFAVYYCQQDDYWP<br>PTFGGGTKVEIK<br>(SEQ ID NO:86)<br><br>CDR1 (SEQ ID NO:90) -<br>RASQSVSSNLA<br>CDR2 (SEQ ID NO:91) - GASTRAT<br>CDR3 (SEQ ID NO:92) -<br>QQDDYWPPT          |
| ADI-29379<br>(E79) | QVQLVQSGAEVKKPGASVKVSKAS<br>GYTFTSYMHVWRQAPGQGLEWM<br>GIINPSGGSTSYAQKFQGRVTMTRDT<br>STSTVYMELSSLRSEDVAVYYCARG<br>APNYGDTTHDYYYMDVWGKGTVT<br>VSS<br>(SEQ ID NO:133)<br><br>CDR1 (SEQ ID NO:135) - YTFTSYMH<br>CDR2 (SEQ ID NO:136) -<br>IINPSGGSTSYAQKFQG<br>CDR3 (SEQ ID NO:137) -<br>ARGAPNYGDTTHDYYYMDV | EIVMTQSPATLSVSPGERATLSCR<br>ASQSVSSNLAWYQQKPGQAPRLI<br>IYGASTRATGIPARFSGSGSGTEFT<br>LTISSLQSEDFAVYYCQQYDDWP<br>FTFGGGTKVEIK<br>(SEQ ID NO:134)<br><br>CDR1 (SEQ ID NO:138) -<br>RASQSVSSNLA<br>CDR2 (SEQ ID NO:139) -<br>GASTRAT<br>CDR3 (SEQ ID NO:140) -<br>QQYDDWPPT |

**[00102]** Alternatively, a heavy chain variable domain defined by SEQ ID NO:49 can be paired with a light chain variable domain defined by SEQ ID NO:50 to form an antigen-binding site that can bind to NKG2D, as illustrated in US 9,273,136.

QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFI  
 RYDGSNKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKDRGLGDGT  
 YFDYWGQGTTVTVSS (SEQ ID NO:49)

5 QSALTQPASVSGSPGQSITISCSGSSSNIGNNAVNWYQQLPGKAPKLLIYYDDL  
 LPSGVSDRFSGSKSGTSAFLAISGLQSEDEADYYCAA WDDSLNGPVFGGGTKLTVL  
 (SEQ ID NO:50)

[00103] Alternatively, a heavy chain variable domain defined by SEQ ID NO:51 can be paired with a light chain variable domain defined by SEQ ID NO:52 to form an antigen-binding site that can bind to NKG2D, as illustrated in US 7,879,985.

10 QVHLQESGPGLVKPSETLSLTCTVSDDISSYYSWIRQPPGKGLEWIGHISYS  
 GSANYNPSLKSRTISVDTSKNQFSLKLSSVTAADTAVYYCANWDDAFNIWGQGT  
 MVTVSS (SEQ ID NO:51)

15 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASS  
 RATGIPDRFSGSGGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (SEQ  
 ID NO:52)

[00104] Table 2 lists peptide sequences of heavy chain variable domains and light chain variable domains that, in combination, can bind to CD33.

| Table 2    |   |   |
|------------|---|---|
| Clones     | Heavy chain variable domain peptide sequence  | Light chain variable domain peptide sequence  |
| Lintuzumab | QVQLVQSGAEVKKPGSSVKV SCKA<br>SGYTFTDYNMHWVRQAPGQGLEW<br>IGYIYPYNGGTGYNQKFKSKATITA<br>DESTNTAYMELSSLRSEDTAVYYC<br>ARGRPAMDYWGQGT LVTVSS<br>(SEQ ID NO:93)<br><br>CDR1 (SEQ ID NO:95) - GYTFTDY<br>CDR2 (SEQ ID NO:96) -<br>YIYPYNGGTG<br>CDR3 (SEQ ID NO:97) - GRPAMDY | DIQMTQSPSSLSASVGD RVTITCRA<br>SESVDNYGISFMNWFQQKPGKAP<br>KLLIYAASNQGS GVP SRFSGSGSGT<br>DFTLTISLQPDDFATYYCQ QSKEV<br>PWTFGQGTKVEIK<br>(SEQ ID NO:94)<br><br>CDR1(SEQ ID NO:98) -<br>ESVDNYGISFMN<br>CDR2 (SEQ ID NO:99) - AASNQGS<br>CDR3 (SEQ ID NO:100) - |

|                                    |  |  |
|------------------------------------|--|--|
|                                    |  | QQSKEVPWT  |
| Gemtuzumab                         | EVQLVQSGAEVKKPGSSVKVSCKA<br>SGYTITDSNIHWVRQAPGQSLEWIG<br>YIYPYNGGTDYNQKFKNRATLTVD<br>NPTNTAYMELSSLRSEDFAFYVCV<br>NGNPWLAYWGQGLTVTVSS<br>(SEQ ID NO:101)<br><br>CDR1 (SEQ ID NO:103) - GYTITDS<br>CDR2 (SEQ ID NO:104) -<br>YIYPYNGGTD<br>CDR3 (SEQ ID NO:105) -<br>GNPWLAY | DIQLTQSPSTLSASVGDRVTITCRA<br>SESLDNYGIRFLTWVQKPGKAPK<br>LLMYAASNQGSVPSRFSGSGSGT<br>EFTLTISLQPDDEFATYYCQQTKEV<br>PWSFGQGTKVEVK<br>(SEQ ID NO:102)<br><br>CDR1 (SEQ ID NO:106) -<br>ESLDNYGIRFLT<br>CDR2 (SEQ ID NO:107) - AASNQGS<br>CDR3 (SEQ ID NO:108) -<br>QQTKEVPWS    |
| anti-CD33<br>(US<br>7,557,189)     | QVQLQQPGAEEVVKPGASVKMSCK<br>ASGYTFTSYIHWIKQTPGQGLEW<br>VGVIIYPGNDDISYNQKFQGKATLT<br>ADKSSTTAYMQLSSLTSEDSAVYY<br>CAREVRLRYFDVWGQGTITVTVSS<br>(SEQ ID NO:109)<br><br>CDR1 (SEQ ID NO:111) - GYTFTSY<br>CDR2 (SEQ ID NO:112) - YPGNDD<br>CDR3 (SEQ ID NO:113) -<br>EVRLRYFDV  | EIVLTQSPGSLAVSPGERVTMSCKS<br>SQSVFFSSSQKNYLAWYQQIPGQS<br>PRLLIYWASTRESGVPDRFTGSGS<br>GTDFTLTISVQPEDLAIYYCHQYL<br>SSRTFGQGTKLEIKR<br>(SEQ ID NO:110)<br><br>CDR1 (SEQ ID NO:114) -<br>QSVFFSSSQKNYLA<br>CDR2 (SEQ ID NO:115) - WASTRES<br>CDR3 (SEQ ID NO:116) -<br>HQYLSRT |
| vadastuximab<br>(US<br>13/804,227) | QVQLVQSGAEVKKPGASVKVSCK<br>ASGYTFTNYDINWVRQAPGQGLE<br>WIGWIYPGDGSKYNEKFKAKATL<br>TADTSTSTAYMELRSLRSDDTAVY<br>YCASGYEDAMDYWGQGTITVTVSS<br>A<br>(SEQ ID NO:117)<br><br>CDR1 (SEQ ID NO:119): GYTFTNY   | DIQMTQSPSSLSASVGDRVTINCK<br>ASQDINSYLSWFQKPGKAPKTLI<br>YRANRLVDGVPSPRFSGSGSGQDYT<br>LTISSLQPEDFATYYCLQYDEFPLT<br>FGGGTKVEIKR<br>(SEQ ID NO:118)<br><br>CDR1 (SEQ ID NO:122): QDINSYLS<br>CDR2 (SEQ ID NO:123): RANRLVD   |

|  |   |                                    |
|--|---|------------------------------------|
|  | CDR2 (SEQ ID NO:120): YPGDGS<br>CDR3 (SEQ ID NO:121):<br>GYEDAMDY | CDR3 (SEQ ID NO:124):<br>LQYDEFPLT |
|--|---|------------------------------------|

[00105] Alternatively, novel antigen-binding sites that can bind to CD33 can be identified by screening for binding to the amino acid sequence defined by SEQ ID NO:53.

SEQ ID NO:53

5 MPLLLLLLPLLWAGALAMPNFWLQVQESVTVQEGLCVLVPCTFFHPIPIYYDKNSPV  
 HGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDN  
 GSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCVSWACEQ  
 GTPPIFSWLSAAPTSLGPRTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLN  
 VTYVPQNPTTGIFPGDGSQKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRK  
 10 AARTAVGRNDTHPTTGSASPKHQKSKLHGPTETSSCSGAAPTVMDEELHYASLN  
 FHGMNPSKDTSTEYSEVRTQ

[00106] Within the Fc domain, CD16 binding is mediated by the hinge region and the CH2 domain. For example, within human IgG1, the interaction with CD16 is primarily focused on amino acid residues Asp 265 – Glu 269, Asn 297 – Thr 299, Ala 327 – Ile 332, Leu 234 –  
 15 Ser 239, and carbohydrate residue N-acetyl-D-glucosamine in the CH2 domain (*see*,  
 Sondermann *et al*, Nature, 406 (6793):267-273). Based on the known domains, mutations can be selected to enhance or reduce the binding affinity to CD16, such as by using phage-  
 displayed libraries or yeast surface-displayed cDNA libraries, or can be designed based on the known three-dimensional structure of the interaction.

20 [00107] The assembly of heterodimeric antibody heavy chains can be accomplished by expressing two different antibody heavy chain sequences in the same cell, which may lead to the assembly of homodimers of each antibody heavy chain as well as assembly of heterodimers. Promoting the preferential assembly of heterodimers can be accomplished by incorporating different mutations in the CH3 domain of each antibody heavy chain constant  
 25 region as shown in US13/494870, US16/028850, US11/533709, US12/875015, US13/289934, US14/773418, US12/811207, US13/866756, US14/647480, and US14/830336. For example, mutations can be made in the CH3 domain based on human IgG1 and incorporating distinct pairs of amino acid substitutions within a first polypeptide and a second polypeptide that allow these two chains to selectively heterodimerize with each  
 30 other. The positions of amino acid substitutions illustrated below are all numbered according to the EU index as in Kabat.

[00108] In one scenario, an amino acid substitution in the first polypeptide replaces the original amino acid with a larger amino acid, selected from arginine (R), phenylalanine (F), tyrosine (Y) or tryptophan (W), and at least one amino acid substitution in the second polypeptide replaces the original amino acid(s) with a smaller amino acid(s), chosen from alanine (A), serine (S), threonine (T), or valine (V), such that the larger amino acid substitution (a protuberance) fits into the surface of the smaller amino acid substitutions (a cavity). For example, one polypeptide can incorporate a T366W substitution, and the other can incorporate three substitutions including T366S, L368A, and Y407V.

[00109] An antibody heavy chain variable domain of the invention can optionally be coupled to an amino acid sequence at least 90% identical to an antibody constant region, such as an IgG constant region including hinge, CH2 and CH3 domains with or without CH1 domain. In some embodiments, the amino acid sequence of the constant region is at least 90% identical to a human antibody constant region, such as a human IgG1 constant region, an IgG2 constant region, IgG3 constant region, or IgG4 constant region. In some other embodiments, the amino acid sequence of the constant region is at least 90% identical to an antibody constant region from another mammal, such as rabbit, dog, cat, mouse, or horse. One or more mutations can be incorporated into the constant region as compared to human IgG1 constant region, for example at Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411 and/or K439. Exemplary substitutions include, for example, Q347E, Q347R, Y349S, Y349K, Y349T, Y349D, Y349E, Y349C, T350V, L351K, L351D, L351Y, S354C, E356K, E357Q, E357L, E357W, K360E, K360W, Q362E, S364K, S364E, S364H, S364D, T366V, T366I, T366L, T366M, T366K, T366W, T366S, L368E, L368A, L368D, K370S, N390D, N390E, K392L, K392M, K392V, K392F, K392D, K392E, T394F, T394W, D399R, D399K, D399V, S400K, S400R, D401K, F405A, F405T, Y407A, Y407I, Y407V, K409F, K409W, K409D, T411D, T411E, K439D, and K439E.

[00110] In certain embodiments, mutations that can be incorporated into the CH1 of a human IgG1 constant region may be at amino acid V125, F126, P127, T135, T139, A140, F170, P171, and/or V173. In certain embodiments, mutations that can be incorporated into the C<sub>κ</sub> of a human IgG1 constant region may be at amino acid E123, F116, S176, V163, S174, and/or T164.

[00111] Amino acid substitutions could be selected from the following sets of substitutions shown in Table 3.

| Table 3 |                   |                    |
|---------|-------------------|--------------------|
|         | First Polypeptide | Second Polypeptide |
| Set 1   | S364E/F405A       | Y349K/T394F        |
| Set 2   | S364H/D401K       | Y349T/T411E        |
| Set 3   | S364H/T394F       | Y349T/F405A        |
| Set 4   | S364E/T394F       | Y349K/F405A        |
| Set 5   | S364E/T411E       | Y349K/D401K        |
| Set 6   | S364D/T394F       | Y349K/F405A        |
| Set 7   | S364H/F405A       | Y349T/T394F        |
| Set 8   | S364K/E357Q       | L368D/K370S        |
| Set 9   | L368D/K370S       | S364K              |
| Set 10  | L368E/K370S       | S364K              |
| Set 11  | K360E/Q362E       | D401K              |
| Set 12  | L368D/K370S       | S364K/E357L        |
| Set 13  | K370S             | S364K/E357Q        |
| Set 14  | F405L             | K409R              |
| Set 15  | K409R             | F405L              |

**[00112]** Alternatively, amino acid substitutions could be selected from the following sets of substitutions shown in Table 4.

| Table 4 |                   |                    |
|---------|-------------------|--------------------|
|         | First Polypeptide | Second Polypeptide |
| Set 1   | K409W             | D399V/F405T        |
| Set 2   | Y349S             | E357W              |
| Set 3   | K360E             | Q347R              |
| Set 4   | K360E/K409W       | Q347R/D399V/F405T  |
| Set 5   | Q347E/K360E/K409W | Q347R/D399V/F405T  |
| Set 6   | Y349S/K409W       | E357W/D399V/F405T  |

**[00113]** Alternatively, amino acid substitutions could be selected from the following set of  
5 substitutions shown in Table 5.

| Table 5 |                   |                    |
|---------|-------------------|--------------------|
|         | First Polypeptide | Second Polypeptide |
| Set 1   | T366K/L351K       | L351D/L368E        |
| Set 2   | T366K/L351K       | L351D/Y349E        |
| Set 3   | T366K/L351K       | L351D/Y349D        |
| Set 4   | T366K/L351K       | L351D/Y349E/L368E  |
| Set 5   | T366K/L351K       | L351D/Y349D/L368E  |
| Set 6   | E356K/D399K       | K392D/K409D        |

[00114] Alternatively, at least one amino acid substitution in each polypeptide chain could be selected from Table 6.

| Table 6  |   |
|--|---|
| First Polypeptide                                      | Second Polypeptide  |
| L351Y, D399R, D399K, S400K, S400R, Y407A, Y407I, Y407V | T366V, T366I, T366L, T366M, N390D, N390E, K392L, K392M, K392V, K392F, K392D, K392E, K409F, K409W, T411D and T411E |

[00115] Alternatively, at least one amino acid substitutions could be selected from the following set of substitutions in Table 7, where the position(s) indicated in the First Polypeptide column is replaced by any known negatively-charged amino acid, and the position(s) indicated in the Second Polypeptide Column is replaced by any known positively-charged amino acid.

| Table 7                   |                     |
|---------------------------|---------------------|
| First Polypeptide         | Second Polypeptide  |
| K392, K370, K409, or K439 | D399, E356, or E357 |

[00116] Alternatively, at least one amino acid substitutions could be selected from the following set of in Table 8, where the position(s) indicated in the First Polypeptide column is replaced by any known positively-charged amino acid, and the position(s) indicated in the Second Polypeptide Column is replaced by any known negatively-charged amino acid.



|                     |                           |
|---------------------|---------------------------|
| Table 8             |                           |
| First Polypeptide   | Second Polypeptide        |
| D399, E356, or E357 | K409, K439, K370, or K392 |

[00117] Alternatively, amino acid substitutions could be selected from the following set in Table 9.

|                                |                                |
|--------------------------------|--------------------------------|
| Table 9                        |                                |
| First Polypeptide              | Second Polypeptide             |
| T350V, L351Y, F405A, and Y407V | T350V, T366L, K392L, and T394W |

[00118] Alternatively, or in addition, the structural stability of a heteromultimer protein may be increased by introducing S354C on either of the first or second polypeptide chain, and Y349C on the opposing polypeptide chain, which forms an artificial disulfide bridge within the interface of the two polypeptides.

[00119] The multi-specific proteins described above can be made using recombinant DNA technology well known to a skilled person in the art. For example, a first nucleic acid sequence encoding the first immunoglobulin heavy chain can be cloned into a first expression vector; a second nucleic acid sequence encoding the second immunoglobulin heavy chain can be cloned into a second expression vector; a third nucleic acid sequence encoding the immunoglobulin light chain can be cloned into a third expression vector; the first, second, and third expression vectors can be stably transfected together into host cells to produce the multimeric proteins.

[00120] To achieve the highest yield of the multi-specific protein, different ratios of the first, second, and third expression vector can be explored to determine the optimal ratio for transfection into the host cells. After transfection, single clones can be isolated for cell bank generation using methods known in the art, such as limited dilution, ELISA, FACS, microscopy, or Clonepix.

[00121] Clones can be cultured under conditions suitable for bio-reactor scale-up and maintained expression of the multi-specific protein. The multi-specific proteins can be isolated and purified using methods known in the art including centrifugation, depth filtration, cell lysis, homogenization, freeze-thawing, affinity purification, gel filtration, ion exchange chromatography, hydrophobic interaction exchange chromatography, and mixed-mode chromatography.

## II. Characteristics of the multi-specific proteins

[00122] In certain embodiments, the multi-specific proteins described herein, which include an NKG2D-binding domain and a binding domain for CD33, bind to cells expressing human NKG2D. In certain embodiments, the multi-specific proteins bind to the tumor associated antigen CD33 at a comparable level to that of a monoclonal antibody having the same CD33-binding domain. However, the multi-specific proteins described herein can be more effective in reducing tumor growth and killing cancer cells expressing CD33 than the corresponding CD33 monoclonal antibodies.

[00123] In certain embodiments, the multi-specific proteins described herein, which include an NKG2D-binding domain and a binding domain for CD33, can activate primary human NK cells when culturing with tumor cells expressing the antigen CD33. NK cell activation is marked by the increase in CD107a degranulation and IFN $\gamma$  cytokine production. Furthermore, compared to a monoclonal antibody that includes the same CD33-binding domain, the multi-specific proteins show superior activation of human NK cells in the presence of tumor cells expressing the antigen CD33.

[00124] In certain embodiments, the multi-specific proteins described herein, which include an NKG2D-binding domain and a binding domain for CD33, can enhance the activity of rested and IL-2-activated human NK cells in the presence of tumor cells expressing the antigen CD33.

[00125] In certain embodiments, the multi-specific proteins described herein, which include an NKG2D-binding domain and a binding domain for a tumor associated antigen CD33, can enhance the cytotoxic activity of rested and IL-2-activated human NK cells in the presence of tumor cells expressing the antigen CD33. In certain embodiments, compared to the corresponding monoclonal antibodies, the multi-specific proteins can offer an advantage against tumor cells expressing medium and low CD33.

[00126] In certain embodiments, the multi-specific proteins described herein can be advantageous in treating cancers with high expression of Fc receptor (FcR), or cancers residing in a tumor microenvironment with high levels of FcR, compared to the corresponding CD33 monoclonal antibodies. Monoclonal antibodies exert their effects on tumor growth through multiple mechanisms including ADCC, CDC, phagocytosis, and signal blockade amongst others. Amongst Fc $\gamma$ Rs, CD16 has the lowest affinity for IgG Fc; Fc $\gamma$ RI (CD64) is the high-affinity FcR, which binds about 1000 times more strongly to IgG Fc than CD16. CD64 is normally expressed on many hematopoietic lineages such as the myeloid lineage, and can be expressed on tumors derived from these cell types, such as acute myeloid

leukemia (AML). Immune cells infiltrating into the tumor, such as MDSCs and monocytes, also express CD64 and are known to infiltrate the tumor microenvironment. Expression of CD64 by the tumor or in the tumor microenvironment can have a detrimental effect on monoclonal antibody therapy. Expression of CD64 in the tumor microenvironment makes it difficult for these antibodies to engage CD16 on the surface of NK cells, as the antibodies prefer to bind the high-affinity receptor. The multi-specific proteins, through targeting two activating receptors on the surface of NK cells, can overcome the detrimental effect of CD64 expression (either on tumor or tumor microenvironment) on monoclonal antibody therapy. Regardless of CD64 expression on the tumor cells, the multi-specific proteins are able to mediate human NK cell responses against all tumor cells, because dual targeting of two activating receptors on NK cells provides stronger specific binding to NK cells.

**[00127]** In some embodiments, the multi-specific proteins described herein can provide a better safety profile through reduced on-target off-tumor side effects. Natural killer cells and CD8 T cells are both able to directly lyse tumor cells, although the mechanisms through which NK cells and CD8 T cell recognize normal self from tumor cells differ. The activity of NK cells is regulated by the balance of signals from activating (NCRs, NKG2D, CD16, *etc.*) and inhibitory (KIRs, NKG2A, *etc.*) receptors. The balance of these activating and inhibitory signals allow NK cells to determine healthy self-cells from stressed, virally infected, or transformed self-cells. This “built-in” mechanism of self-tolerance will help protect normal healthy tissue from NK cell responses. To extend this principle, the self-tolerance of NK cells will allow TriNKETs to target antigens expressed both on self and tumor without off tumor side effects, or with an increased therapeutic window. Unlike natural killer cells, T cells require recognition of a specific peptide presented by MHC molecules for activation and effector functions. T cells have been the primary target of immunotherapy, and many strategies have been developed to redirect T cell responses against the tumor. T cell bispecifics, checkpoint inhibitors, and CAR-T cells have all been approved by the FDA, but often suffer from dose-limiting toxicities. T cell bispecifics and CAR-T cells work around the TCR-MHC recognition system by using binding domains to target antigens on the surface of tumor cells, and using engineered signaling domains to transduce the activation signals into the effector cell. Although effective at eliciting an anti-tumor immune response these therapies are often coupled with cytokine release syndrome (CRS), and on-target off-tumor side effects. The multi-specific proteins are unique in this context as they will not “override” the natural systems of NK cell activation and inhibition. Instead, the multi-specific proteins

are designed to sway the balance, and provide additional activation signals to the NK cells, while maintaining NK tolerance to healthy self.

[00128] In some embodiments, the multi-specific proteins described herein can delay progression of the tumor more effectively than the corresponding CD33 monoclonal  
5 antibodies that include the same CD33-binding domain. In some embodiments, the multi-specific proteins described herein can be more effective against cancer metastases than the corresponding CD33 monoclonal antibodies that include the same CD33-binding domain.

### III. THERAPEUTIC APPLICATIONS

[00129] The invention provides methods for treating cancer using a multi-specific binding  
10 protein described herein and/or a pharmaceutical composition described herein. The methods may be used to treat a variety of cancers which express CD33 by administering to a patient in need thereof a therapeutically effective amount of a multi-specific binding protein described herein.

[00130] The therapeutic method can be characterized according to the cancer to be treated.  
15 For example, in certain embodiments, the cancer is AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, and ALLs.

[00131] In certain other embodiments, the cancer is brain cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia,  
20 lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer. In yet other embodiments, the cancer is a squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, neuroblastoma, sarcoma (*e.g.*, an angiosarcoma or chondrosarcoma), larynx cancer, parotid cancer, biliary tract cancer, thyroid cancer, acral lentiginous melanoma, actinic keratoses,  
25 acute lymphocytic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, anal canal cancer, anal cancer, anorectum cancer, astrocytic tumor, bartholin gland carcinoma, basal cell carcinoma, biliary cancer, bone cancer, bone marrow cancer, bronchial cancer, bronchial gland carcinoma, carcinoid, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma/carcinoma, chronic  
30 lymphocytic leukemia, chronic myeloid leukemia, clear cell carcinoma, connective tissue cancer, cystadenoma, digestive system cancer, duodenum cancer, endocrine system cancer, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, endothelial cell cancer, ependymal cancer, epithelial cell

cancer, Ewing's sarcoma, eye and orbit cancer, female genital cancer, focal nodular hyperplasia, gallbladder cancer, gastric antrum cancer, gastric fundus cancer, gastrinoma, glioblastoma, glucagonoma, heart cancer, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatobiliary cancer, hepatocellular carcinoma, Hodgkin's disease, ileum cancer, insulinoma, intraepithelial neoplasia, 5 interepithelial squamous cell neoplasia, intrahepatic bile duct cancer, invasive squamous cell carcinoma, jejunum cancer, joint cancer, Kaposi's sarcoma, pelvic cancer, large cell carcinoma, large intestine cancer, leiomyosarcoma, lentigo maligna melanomas, lymphoma, male genital cancer, malignant melanoma, malignant mesothelial tumors, medulloblastoma, 10 medulloepithelioma, meningeal cancer, mesothelial cancer, metastatic carcinoma, mouth cancer, mucoepidermoid carcinoma, multiple myeloma, muscle cancer, nasal tract cancer, nervous system cancer, neuroepithelial adenocarcinoma nodular melanoma, non-epithelial skin cancer, non-Hodgkin's lymphoma, oat cell carcinoma, oligodendroglial cancer, oral cavity cancer, osteosarcoma, papillary serous adenocarcinoma, penile cancer, pharynx cancer, 15 pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, rectal cancer, renal cell carcinoma, respiratory system cancer, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, sinus cancer, skin cancer, small cell carcinoma, small intestine cancer, smooth muscle cancer, soft tissue cancer, somatostatin-secreting tumor, spine cancer, squamous cell carcinoma, striated muscle cancer, submesothelial cancer, superficial 20 spreading melanoma, T cell leukemia, tongue cancer, undifferentiated carcinoma, ureter cancer, urethra cancer, urinary bladder cancer, urinary system cancer, uterine cervix cancer, uterine corpus cancer, uveal melanoma, vaginal cancer, verrucous carcinoma, VIPoma, vulva cancer, well differentiated carcinoma, or Wilms tumor.

**[00132]** In certain other embodiments, the cancer is non-Hodgkin's lymphoma, such as a 25 B-cell lymphoma or a T-cell lymphoma. In certain embodiments, the non-Hodgkin's lymphoma is a B-cell lymphoma, such as a diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, Burkitt 30 lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, or primary central nervous system (CNS) lymphoma. In certain other embodiments, the non-Hodgkin's lymphoma is a T-cell lymphoma, such as a precursor T-lymphoblastic lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal natural killer/T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous

panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma, or peripheral T-cell lymphoma.

[00133] The cancer to be treated can be characterized according to the presence of a particular antigen expressed on the surface of the cancer cell. In certain embodiments, the cancer cell can express one or more of the following in addition to CD33: CD2, CD19, CD20, CD30, CD38, CD40, CD52, CD70, EGFR/ERBB1, IGF1R, HER3/ERBB3, HER4/ERBB4, MUC1, cMET, SLAMF7, PSCA, MICA, MICB, TRAILR1, TRAILR2, MAGE-A3, B7.1, B7.2, CTLA4, and PD1.

#### IV. COMBINATION THERAPY

10 [00134] Another aspect of the invention provides for combination therapy. Multi-specific binding proteins described herein be used in combination with additional therapeutic agents to treat the cancer.

[00135] Exemplary therapeutic agents that may be used as part of a combination therapy in treating cancer, include, for example, radiation, mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozocin, nimustine, vindesine, flutamide, drogenil, butocin, carmofur, razoxane, sizofilan, carboplatin, mitolactol, tegafur, ifosfamide, prednimustine, picibanil, levamisole, teniposide, improsulfan, enocitabine, lisuride, oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, formestane, interferon-alpha, interferon-2 alpha, interferon-beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, luteinizing hormone releasing factor and variations of the aforementioned agents that may exhibit differential binding to its cognate receptor, and increased or decreased serum half-life.

[00136] An additional class of agents that may be used as part of a combination therapy in treating cancer is immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include agents that inhibit one or more of (i) cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), (ii) programmed cell death protein 1 (PD1), (iii) PDL1, (iv) LAG3, (v) B7-H3, (vi) B7-H4, and (vii) TIM3. The CTLA4 inhibitor ipilimumab has been approved by the United States Food and Drug Administration for treating melanoma.

[00137] Yet other agents that may be used as part of a combination therapy in treating cancer are monoclonal antibody agents that target non-checkpoint targets (*e.g.*, herceptin) and non-cytotoxic agents (*e.g.*, tyrosine-kinase inhibitors).

[00138] Yet other categories of anti-cancer agents include, for example: (i) an inhibitor  
5 selected from an ALK Inhibitor, an ATR Inhibitor, an A2A Antagonist, a Base Excision  
Repair Inhibitor, a Bcr-Abl Tyrosine Kinase Inhibitor, a Bruton's Tyrosine Kinase Inhibitor, a  
CDC7 Inhibitor, a CHK1 Inhibitor, a Cyclin-Dependent Kinase Inhibitor, a DNA-PK  
Inhibitor, an Inhibitor of both DNA-PK and mTOR, a DNMT1 Inhibitor, a DNMT1 Inhibitor  
plus 2-chloro-deoxyadenosine, an HDAC Inhibitor, a Hedgehog Signaling Pathway Inhibitor,  
10 an IDO Inhibitor, a JAK Inhibitor, a mTOR Inhibitor, a MEK Inhibitor, a MELK Inhibitor, a  
MTH1 Inhibitor, a PARP Inhibitor, a Phosphoinositide 3-Kinase Inhibitor, an Inhibitor of  
both PARP1 and DHODH, a Proteasome Inhibitor, a Topoisomerase-II Inhibitor, a Tyrosine  
Kinase Inhibitor, a VEGFR Inhibitor, and a WEE1 Inhibitor; (ii) an agonist of OX40, CD137,  
CD40, GITR, CD27, HVEM, TNFRSF25, or ICOS; and (iii) a cytokine selected from IL-12,  
15 IL-15, GM-CSF, and G-CSF.

[00139] Proteins of the invention can also be used as an adjunct to surgical removal of the primary lesion.

[00140] The amount of multi-specific binding protein and additional therapeutic agent and the relative timing of administration may be selected in order to achieve a desired combined  
20 therapeutic effect. For example, when administering a combination therapy to a patient in  
need of such administration, the therapeutic agents in the combination, or a pharmaceutical  
composition or compositions comprising the therapeutic agents, may be administered in any  
order such as, for example, sequentially, concurrently, together, simultaneously and the like.  
Further, for example, a multi-specific binding protein may be administered during a time  
25 when the additional therapeutic agent(s) exerts its prophylactic or therapeutic effect, or *vice versa*.

## V. PHARMACEUTICAL COMPOSITIONS

[00141] The present disclosure also features pharmaceutical compositions that contain a therapeutically effective amount of a protein described herein. The composition can be  
30 formulated for use in a variety of drug delivery systems. One or more physiologically  
acceptable excipients or carriers can also be included in the composition for proper  
formulation. Suitable formulations for use in the present disclosure are found in Remington's

Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief review of methods for drug delivery, see, *e.g.*, Langer (Science 249:1527-1533, 1990).

[00142] The intravenous drug delivery formulation of the present disclosure may be contained in a bag, a pen, or a syringe. In certain embodiments, the bag may be connected to a channel comprising a tube and/or a needle. In certain embodiments, the formulation may be a lyophilized formulation or a liquid formulation. In certain embodiments, the formulation may freeze-dried (lyophilized) and contained in about 12-60 vials. In certain embodiments, the formulation may be freeze-dried and 45 mg of the freeze-dried formulation may be contained in one vial. In certain embodiments, the about 40 mg – about 100 mg of freeze-dried formulation may be contained in one vial. In certain embodiments, freeze dried formulation from 12, 27, or 45 vials are combined to obtained a therapeutic dose of the protein in the intravenous drug formulation. In certain embodiments, the formulation may be a liquid formulation and stored as about 250 mg/vial to about 1000 mg/vial. In certain embodiments, the formulation may be a liquid formulation and stored as about 600 mg/vial. In certain embodiments, the formulation may be a liquid formulation and stored as about 250 mg/vial.

[00143] This present disclosure could exist in a liquid aqueous pharmaceutical formulation including a therapeutically effective amount of the protein in a buffered solution forming a formulation.

[00144] These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as-is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparations typically will be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, such as 7 to 7.5. The resulting compositions in solid form may be packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents. The composition in solid form can also be packaged in a container for a flexible quantity.

[00145] In certain embodiments, the present disclosure provides a formulation with an extended shelf life including the protein of the present disclosure, in combination with mannitol, citric acid monohydrate, sodium citrate, disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, polysorbate 80, water, and sodium hydroxide.

[00146] In certain embodiments, an aqueous formulation is prepared including the protein of the present disclosure in a pH-buffered solution. The buffer of this invention may have a



pH ranging from about 4 to about 8, *e.g.*, from about 4.5 to about 6.0, or from about 4.8 to about 5.5, or may have a pH of about 5.0 to about 5.2. Ranges intermediate to the above recited pH's are also intended to be part of this disclosure. For example, ranges of values using a combination of any of the above recited values as upper and/or lower limits are intended to be included. Examples of buffers that will control the pH within this range include acetate (*e.g.* sodium acetate), succinate (such as sodium succinate), gluconate, histidine, citrate and other organic acid buffers.

**[00147]** In certain embodiments, the formulation includes a buffer system which contains citrate and phosphate to maintain the pH in a range of about 4 to about 8. In certain

embodiments the pH range may be from about 4.5 to about 6.0, or from about pH 4.8 to about 5.5, or in a pH range of about 5.0 to about 5.2. In certain embodiments, the buffer system includes citric acid monohydrate, sodium citrate, disodium phosphate dihydrate, and/or sodium dihydrogen phosphate dihydrate. In certain embodiments, the buffer system includes about 1.3 mg/ml of citric acid (*e.g.*, 1.305 mg/ml), about 0.3 mg/ml of sodium citrate (*e.g.*, 0.305 mg/ml), about 1.5 mg/ml of disodium phosphate dihydrate (*e.g.*, 1.53 mg/ml), about 0.9 mg/ml of sodium dihydrogen phosphate dihydrate (*e.g.*, 0.86), and about 6.2 mg/ml of sodium chloride (*e.g.*, 6.165 mg/ml). In certain embodiments, the buffer system includes 1-1.5 mg/ml of citric acid, 0.25 to 0.5 mg/ml of sodium citrate, 1.25 to 1.75 mg/ml of disodium phosphate dihydrate, 0.7 to 1.1 mg/ml of sodium dihydrogen phosphate dihydrate, and 6.0 to 6.4 mg/ml of sodium chloride. In certain embodiments, the pH of the formulation is adjusted with sodium hydroxide.

**[00148]** A polyol, which acts as a tonicifier and may stabilize the antibody, may also be included in the formulation. The polyol is added to the formulation in an amount which may vary with respect to the desired isotonicity of the formulation. In certain embodiments, the aqueous formulation may be isotonic. The amount of polyol added may also be altered with respect to the molecular weight of the polyol. For example, a lower amount of a monosaccharide (*e.g.*, mannitol) may be added, compared to a disaccharide (such as trehalose). In certain embodiments, the polyol which may be used in the formulation as a tonicity agent is mannitol. In certain embodiments, the mannitol concentration may be about 5 to about 20 mg/ml. In certain embodiments, the concentration of mannitol may be about 7.5 to 15 mg/ml. In certain embodiments, the concentration of mannitol may be about 10-14 mg/ml. In certain embodiments, the concentration of mannitol may be about 12 mg/ml. In certain embodiments, the polyol sorbitol may be included in the formulation.

[00149] A detergent or surfactant may also be added to the formulation. Exemplary detergents include nonionic detergents such as polysorbates (*e.g.*, polysorbates 20, 80 etc.) or poloxamers (*e.g.*, poloxamer 188). The amount of detergent added is such that it reduces aggregation of the formulated antibody and/or minimizes the formation of particulates in the formulation and/or reduces adsorption. In certain embodiments, the formulation may include a surfactant which is a polysorbate. In certain embodiments, the formulation may contain the detergent polysorbate 80 or Tween 80. Tween 80 is a term used to describe polyoxyethylene (20) sorbitanmonooleate (see Fiedler, *Lexikon der Hifsstoffe*, Editio Cantor Verlag Aulendorf, 4th edi., 1996). In certain embodiments, the formulation may contain between about 0.1 mg/mL and about 10 mg/mL of polysorbate 80, or between about 0.5 mg/mL and about 5 mg/mL. In certain embodiments, about 0.1% polysorbate 80 may be added in the formulation.

[00150] In embodiments, the protein product of the present disclosure is formulated as a liquid formulation. The liquid formulation may be presented at a 10 mg/mL concentration in either a USP / Ph Eur type I 50R vial closed with a rubber stopper and sealed with an aluminum crimp seal closure. The stopper may be made of elastomer complying with USP and Ph Eur. In certain embodiments vials may be filled with 61.2 mL of the protein product solution in order to allow an extractable volume of 60 mL. In certain embodiments, the liquid formulation may be diluted with 0.9% saline solution.

[00151] In certain embodiments, the liquid formulation of the disclosure may be prepared as a 10 mg/mL concentration solution in combination with a sugar at stabilizing levels. In certain embodiments the liquid formulation may be prepared in an aqueous carrier. In certain embodiments, a stabilizer may be added in an amount no greater than that which may result in a viscosity undesirable or unsuitable for intravenous administration. In certain embodiments, the sugar may be disaccharides, *e.g.*, sucrose. In certain embodiments, the liquid formulation may also include one or more of a buffering agent, a surfactant, and a preservative.

[00152] In certain embodiments, the pH of the liquid formulation may be set by addition of a pharmaceutically acceptable acid and/or base. In certain embodiments, the pharmaceutically acceptable acid may be hydrochloric acid. In certain embodiments, the base may be sodium hydroxide.

[00153] In addition to aggregation, deamidation is a common product variant of peptides and proteins that may occur during fermentation, harvest/cell clarification, purification, drug substance/drug product storage and during sample analysis. Deamidation is the loss of NH<sub>3</sub>

from a protein forming a succinimide intermediate that can undergo hydrolysis. The succinimide intermediate results in a 17 dalton mass decrease of the parent peptide. The subsequent hydrolysis results in an 18 dalton mass increase. Isolation of the succinimide intermediate is difficult due to instability under aqueous conditions. As such, deamidation is typically detectable as 1 dalton mass increase. Deamidation of an asparagine results in either aspartic or isoaspartic acid. The parameters affecting the rate of deamidation include pH, temperature, solvent dielectric constant, ionic strength, primary sequence, local polypeptide conformation and tertiary structure. The amino acid residues adjacent to Asn in the peptide chain affect deamidation rates. Gly and Ser following an Asn in protein sequences results in a higher susceptibility to deamidation.

**[00154]** In certain embodiments, the liquid formulation of the present disclosure may be preserved under conditions of pH and humidity to prevent deamination of the protein product.

**[00155]** The aqueous carrier of interest herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation. Illustrative carriers include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (*e.g.*, phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.

**[00156]** A preservative may be optionally added to the formulations herein to reduce bacterial action. The addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.

**[00157]** Intravenous (IV) formulations may be the preferred administration route in particular instances, such as when a patient is in the hospital after transplantation receiving all drugs via the IV route. In certain embodiments, the liquid formulation is diluted with 0.9% Sodium Chloride solution before administration. In certain embodiments, the diluted drug product for injection is isotonic and suitable for administration by intravenous infusion.

**[00158]** In certain embodiments, a salt or buffer components may be added in an amount of 10 mM - 200 mM. The salts and/or buffers are pharmaceutically acceptable and are derived from various known acids (inorganic and organic) with "base forming" metals or amines. In certain embodiments, the buffer may be phosphate buffer. In certain embodiments, the buffer may be glycinate, carbonate, citrate buffers, in which case, sodium, potassium or ammonium ions can serve as counterion.

**[00159]** A preservative may be optionally added to the formulations herein to reduce bacterial action. The addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.

[00160] The aqueous carrier of interest herein is one which is pharmaceutically acceptable (safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation. Illustrative carriers include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (*e.g.*, phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.

[00161] This present disclosure could exist in a lyophilized formulation including the proteins and a lyoprotectant. The lyoprotectant may be sugar, *e.g.*, disaccharides. In certain embodiments, the lyoprotectant may be sucrose or maltose. The lyophilized formulation may also include one or more of a buffering agent, a surfactant, a bulking agent, and/or a preservative.

[00162] The amount of sucrose or maltose useful for stabilization of the lyophilized drug product may be in a weight ratio of at least 1:2 protein to sucrose or maltose. In certain embodiments, the protein to sucrose or maltose weight ratio may be of from 1:2 to 1:5.

[00163] In certain embodiments, the pH of the formulation, prior to lyophilization, may be set by addition of a pharmaceutically acceptable acid and/or base. In certain embodiments the pharmaceutically acceptable acid may be hydrochloric acid. In certain embodiments, the pharmaceutically acceptable base may be sodium hydroxide.

[00164] Before lyophilization, the pH of the solution containing the protein of the present disclosure may be adjusted between 6 to 8. In certain embodiments, the pH range for the lyophilized drug product may be from 7 to 8.

[00165] In certain embodiments, a salt or buffer components may be added in an amount of 10 mM - 200 mM. The salts and/or buffers are pharmaceutically acceptable and are derived from various known acids (inorganic and organic) with "base forming" metals or amines. In certain embodiments, the buffer may be phosphate buffer. In certain embodiments, the buffer may be glycinate, carbonate, citrate buffers, in which case, sodium, potassium or ammonium ions can serve as counterion.

[00166] In certain embodiments, a "bulking agent" may be added. A "bulking agent" is a compound which adds mass to a lyophilized mixture and contributes to the physical structure of the lyophilized cake (*e.g.*, facilitates the production of an essentially uniform lyophilized cake which maintains an open pore structure). Illustrative bulking agents include mannitol, glycine, polyethylene glycol and sorbitol. The lyophilized formulations of the present invention may contain such bulking agents.

[00167] A preservative may be optionally added to the formulations herein to reduce bacterial action. The addition of a preservative may, for example, facilitate the production of a multi-use (multiple-dose) formulation.

5 [00168] In certain embodiments, the lyophilized drug product may be constituted with an aqueous carrier. The aqueous carrier of interest herein is one which is pharmaceutically acceptable (*e.g.*, safe and non-toxic for administration to a human) and is useful for the preparation of a liquid formulation, after lyophilization. Illustrative diluents include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), a pH buffered solution (*e.g.*, phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose  
10 solution.

[00169] In certain embodiments, the lyophilized drug product of the current disclosure is reconstituted with either Sterile Water for Injection, USP (SWFI) or 0.9% Sodium Chloride Injection, USP. During reconstitution, the lyophilized powder dissolves into a solution.

15 [00170] In certain embodiments, the lyophilized protein product of the instant disclosure is constituted to about 4.5 mL water for injection and diluted with 0.9% saline solution (sodium chloride solution).

[00171] Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and  
20 mode of administration, without being toxic to the patient.

[00172] The specific dose can be a uniform dose for each patient, for example, 50-5000 mg of protein. Alternatively, a patient's dose can be tailored to the approximate body weight or surface area of the patient. Other factors in determining the appropriate dosage can include the disease or condition to be treated or prevented, the severity of the disease, the route of  
25 administration, and the age, sex and medical condition of the patient. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those skilled in the art, especially in light of the dosage information and assays disclosed herein. The dosage can also be determined through the use of known assays for determining dosages used in conjunction with appropriate dose-response data. An individual patient's  
30 dosage can be adjusted as the progress of the disease is monitored. Blood levels of the targetable construct or complex in a patient can be measured to see if the dosage needs to be adjusted to reach or maintain an effective concentration. Pharmacogenomics may be used to determine which targetable constructs and/or complexes, and dosages thereof, are most likely

to be effective for a given individual (Schmitz *et al.*, *Clinica Chimica Acta* 308: 43-53, 2001; Steimer *et al.*, *Clinica Chimica Acta* 308: 33-41, 2001).

[00173] In general, dosages based on body weight are from about 0.01  $\mu\text{g}$  to about 100 mg per kg of body weight, such as about 0.01  $\mu\text{g}$  to about 100 mg/kg of body weight, about 0.01  $\mu\text{g}$  to about 50 mg/kg of body weight, about 0.01  $\mu\text{g}$  to about 10 mg/kg of body weight, about 0.01  $\mu\text{g}$  to about 1 mg/kg of body weight, about 0.01  $\mu\text{g}$  to about 100  $\mu\text{g}/\text{kg}$  of body weight, about 0.01  $\mu\text{g}$  to about 50  $\mu\text{g}/\text{kg}$  of body weight, about 0.01  $\mu\text{g}$  to about 10  $\mu\text{g}/\text{kg}$  of body weight, about 0.01  $\mu\text{g}$  to about 1  $\mu\text{g}/\text{kg}$  of body weight, about 0.01  $\mu\text{g}$  to about 0.1  $\mu\text{g}/\text{kg}$  of body weight, about 0.1  $\mu\text{g}$  to about 100 mg/kg of body weight, about 0.1  $\mu\text{g}$  to about 50 mg/kg of body weight, about 0.1  $\mu\text{g}$  to about 10 mg/kg of body weight, about 0.1  $\mu\text{g}$  to about 1 mg/kg of body weight, about 0.1  $\mu\text{g}$  to about 100  $\mu\text{g}/\text{kg}$  of body weight, about 0.1  $\mu\text{g}$  to about 10  $\mu\text{g}/\text{kg}$  of body weight, about 0.1  $\mu\text{g}$  to about 1  $\mu\text{g}/\text{kg}$  of body weight, about 1  $\mu\text{g}$  to about 100 mg/kg of body weight, about 1  $\mu\text{g}$  to about 50 mg/kg of body weight, about 1  $\mu\text{g}$  to about 10 mg/kg of body weight, about 1  $\mu\text{g}$  to about 1 mg/kg of body weight, about 1  $\mu\text{g}$  to about 100  $\mu\text{g}/\text{kg}$  of body weight, about 1  $\mu\text{g}$  to about 50  $\mu\text{g}/\text{kg}$  of body weight, about 1  $\mu\text{g}$  to about 10  $\mu\text{g}/\text{kg}$  of body weight, about 10  $\mu\text{g}$  to about 100 mg/kg of body weight, about 10  $\mu\text{g}$  to about 50 mg/kg of body weight, about 10  $\mu\text{g}$  to about 10 mg/kg of body weight, about 10  $\mu\text{g}$  to about 1 mg/kg of body weight, about 10  $\mu\text{g}$  to about 100  $\mu\text{g}/\text{kg}$  of body weight, about 10  $\mu\text{g}$  to about 50  $\mu\text{g}/\text{kg}$  of body weight, about 50  $\mu\text{g}$  to about 100 mg/kg of body weight, about 50  $\mu\text{g}$  to about 50 mg/kg of body weight, about 50  $\mu\text{g}$  to about 10 mg/kg of body weight, about 50  $\mu\text{g}$  to about 1 mg/kg of body weight, about 50  $\mu\text{g}$  to about 100  $\mu\text{g}/\text{kg}$  of body weight, about 100  $\mu\text{g}$  to about 100 mg/kg of body weight, about 100  $\mu\text{g}$  to about 50 mg/kg of body weight, about 100  $\mu\text{g}$  to about 10 mg/kg of body weight, about 100  $\mu\text{g}$  to about 1 mg/kg of body weight, about 1 mg to about 100 mg/kg of body weight, about 1 mg to about 50 mg/kg of body weight, about 1 mg to about 10 mg/kg of body weight, about 10 mg to about 100 mg/kg of body weight, about 10 mg to about 50 mg/kg of body weight, about 50 mg to about 100 mg/kg of body weight.

[00174] Doses may be given once or more times daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the targetable construct or complex in bodily fluids or tissues. Administration of the present invention could be intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, intracavitary, by perfusion through a catheter or by direct intralesional injection.

This may be administered once or more times daily, once or more times weekly, once or more times monthly, and once or more times annually.

[00175] The description above describes multiple aspects and embodiments of the invention. The patent application specifically contemplates all combinations and  
5 permutations of the aspects and embodiments.

#### EXAMPLES

[00176] The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of  
10 certain aspects and embodiments of the present invention, and is not intended to limit the invention.

#### **Example 1 – NKG2D-binding domains bind to NKG2D**

##### NKG2D-binding domains bind to purified recombinant NKG2D

[00177] The nucleic acid sequences of human, mouse or cynomolgus NKG2D  
15 ectodomains were fused with nucleic acid sequences encoding human IgG1 Fc domains and introduced into mammalian cells to be expressed. After purification, NKG2D-Fc fusion proteins were adsorbed to wells of microplates. After blocking the wells with bovine serum albumin to prevent non-specific binding, NKG2D-binding domains were titrated and added to  
20 the wells pre-adsorbed with NKG2D-Fc fusion proteins. Primary antibody binding was detected using a secondary antibody which was conjugated to horseradish peroxidase and specifically recognizes a human kappa light chain to avoid Fc cross-reactivity. 3,3',5,5'-Tetramethylbenzidine (TMB), a substrate for horseradish peroxidase, was added to the wells to visualize the binding signal, whose absorbance was measured at 450 nM and corrected at  
25 540 nM. An NKG2D-binding domain clone, an isotype control or a positive control (selected from SEQ ID NOs:45-48, or anti-mouse NKG2D clones MI-6 and CX-5 available at eBioscience) was added to each well.

[00178] The isotype control showed minimal binding to recombinant NKG2D-Fc proteins, while the positive control bound strongest to the recombinant antigens. NKG2D-binding  
30 domains produced by all clones demonstrated binding across human, mouse, and cynomolgus recombinant NKG2D-Fc proteins, although with varying affinities from clone to clone. Generally, each anti-NKG2D clone bound to human (FIG. 3) and cynomolgus (FIG. 4) recombinant NKG2D-Fc with similar affinity, but with lower affinity to mouse (FIG. 5) recombinant NKG2D-Fc.

### NKG2D-binding domains bind to cells expressing NKG2D

[00179] EL4 mouse lymphoma cell lines were engineered to express human or mouse NKG2D - CD3 zeta signaling domain chimeric antigen receptors. An NKG2D-binding clone,  
5 an isotype control or a positive control was used at a 100 nM concentration to stain extracellular NKG2D expressed on the EL4 cells. The antibody binding was detected using fluorophore-conjugated anti-human IgG secondary antibodies. Cells were analyzed by flow cytometry, and fold-over-background (FOB) was calculated using the mean fluorescence intensity (MFI) of NKG2D expressing cells compared to parental EL4 cells.

10 [00180] NKG2D-binding domains produced by all clones bound to EL4 cells expressing human and mouse NKG2D. Positive control antibodies (selected from SEQ ID NO: 45-48, or anti-mouse NKG2D clones MI-6 and CX-5 available at eBioscience) gave the best FOB binding signal. The NKG2D-binding affinity for each clone was similar between cells expressing human NKG2D (FIG. 6) and mouse (FIG. 7) NKG2D.

15

### **Example 2 – NKG2D-binding domains block natural ligand binding to NKG2D**

#### Competition With ULBP-6

[00181] Recombinant human NKG2D-Fc proteins were adsorbed to wells of a microplate, and the wells were blocked with bovine serum albumin reduce non-specific binding. A  
20 saturating concentration of ULBP-6-His-biotin was added to the wells, followed by addition of the NKG2D-binding domain clones. After a 2-hour incubation, wells were washed and ULBP-6-His-biotin that remained bound to the NKG2D-Fc coated wells was detected by streptavidin-conjugated to horseradish peroxidase and TMB substrate. Absorbance was measured at 450 nM and corrected at 540 nM. After subtracting background, specific binding  
25 of NKG2D-binding domains to the NKG2D-Fc proteins was calculated from the percentage of ULBP-6-His-biotin that was blocked from binding to the NKG2D-Fc proteins in wells. The positive control antibody (selected from SEQ ID NOs:45-48) and various NKG2D-binding domains blocked ULBP-6 binding to NKG2D, while isotype control showed little competition with ULBP-6 (FIG. 8).

#### 30 Competition With MICA

[00182] Recombinant human MICA-Fc proteins were adsorbed to wells of a microplate, and the wells were blocked with bovine serum albumin to reduce non-specific binding. NKG2D-Fc-biotin was added to wells followed by NKG2D-binding domains. After



incubation and washing, NKG2D-Fc-biotin that remained bound to MICA-Fc coated wells was detected using streptavidin-HRP and TMB substrate. Absorbance was measured at 450 nM and corrected at 540 nM. After subtracting background, specific binding of NKG2D-binding domains to the NKG2D-Fc proteins was calculated from the percentage of NKG2D-Fc-biotin that was blocked from binding to the MICA-Fc coated wells. The positive control antibody (selected from SEQ ID NOs:45-48) and various NKG2D-binding domains blocked MICA binding to NKG2D, while isotype control showed little competition with MICA (FIG. 9).

#### Competition With Rae-1 delta

10 [00183] Recombinant mouse Rae-1delta-Fc (purchased from R&D Systems) was adsorbed to wells of a microplate, and the wells were blocked with bovine serum albumin to reduce non-specific binding. Mouse NKG2D-Fc-biotin was added to the wells followed by NKG2D-binding domains. After incubation and washing, NKG2D-Fc-biotin that remained bound to Rae-1delta-Fc coated wells was detected using streptavidin-HRP and TMB substrate.

15 Absorbance was measured at 450 nM and corrected at 540 nM. After subtracting background, specific binding of NKG2D-binding domains to the NKG2D-Fc proteins was calculated from the percentage of NKG2D-Fc-biotin that was blocked from binding to the Rae-1delta-Fc coated wells. The positive control (selected from SEQ ID NOs:45-48, or anti-mouse NKG2D clones MI-6 and CX-5 available at eBioscience) and various NKG2D-binding domain clones

20 blocked Rae-1delta binding to mouse NKG2D, while the isotype control antibody showed little competition with Rae-1delta (FIG. 10).

#### **Example 3 – NKG2D-binding domain clones activate NKG2D**

[00184] Nucleic acid sequences of human and mouse NKG2D were fused to nucleic acid sequences encoding a CD3 zeta signaling domain to obtain chimeric antigen receptor (CAR) constructs. The NKG2D-CAR constructs were then cloned into a retrovirus vector using Gibson assembly and transfected into expi293 cells for retrovirus production. EL4 cells were infected with viruses containing NKG2D-CAR together with 8 µg/mL polybrene. 24 hours after infection, the expression levels of NKG2D-CAR in the EL4 cells were analyzed by flow

30 cytometry, and clones which express high levels of the NKG2D-CAR on the cell surface were selected.

[00185] To determine whether NKG2D-binding domains activate NKG2D, they were adsorbed to wells of a microplate, and NKG2D-CAR EL4 cells were cultured on the antibody fragment-coated wells for 4 hours in the presence of brefeldin-A and monensin. Intracellular

TNF-alpha production, an indicator for NKG2D activation, was assayed by flow cytometry. The percentage of TNF-alpha positive cells was normalized to the cells treated with the positive control. All NKG2D-binding domains activated both human NKG2D (FIG. 11) and mouse NKG2D (FIG. 12).

5

#### **Example 4 – NKG2D-binding domains activate NK cells**

##### Primary human NK cells

[00186] Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood buffy coats using density gradient centrifugation. NK cells (CD3<sup>-</sup> CD56<sup>+</sup>) were isolated using negative selection with magnetic beads from PBMCs, and the purity of the isolated NK cells was typically >95%. Isolated NK cells were then cultured in media containing 100 ng/mL IL-2 for 24-48 hours before they were transferred to the wells of a microplate to which the NKG2D-binding domains were adsorbed, and cultured in the media containing fluorophore-conjugated anti-CD107a antibody, brefeldin-A, and monensin.

10

15 Following culture, NK cells were assayed by flow cytometry using fluorophore-conjugated antibodies against CD3, CD56 and IFN-gamma. CD107a and IFN-gamma staining were analyzed in CD3<sup>-</sup> CD56<sup>+</sup> cells to assess NK cell activation. The increase in CD107a/IFN-gamma double-positive cells is indicative of better NK cell activation through engagement of two activating receptors rather than one receptor. NKG2D-binding domains and the positive control (selected from SEQ ID NOs:45-48) showed a higher percentage of NK cells becoming CD107a<sup>+</sup> and IFN-gamma<sup>+</sup> than the isotype control (FIG. 13 & FIG. 14 represent data from two independent experiments, each using a different donor's PBMC for NK cell preparation).

20

##### Primary mouse NK cells

25 [00187] Spleens were obtained from C57Bl/6 mice and crushed through a 70 µm cell strainer to obtain single cell suspension. Cells were pelleted and resuspended in ACK lysis buffer (purchased from Thermo Fisher Scientific #A1049201; 155mM ammonium chloride, 10mM potassium bicarbonate, 0.01mM EDTA) to remove red blood cells. The remaining cells were cultured with 100 ng/mL hIL-2 for 72 hours before being harvested and prepared

30 for NK cell isolation. NK cells (CD3<sup>-</sup> NK1.1<sup>+</sup>) were then isolated from spleen cells using a negative depletion technique with magnetic beads with typically >90% purity. Purified NK cells were cultured in media containing 100 ng/mL mIL-15 for 48 hours before they were transferred to the wells of a microplate to which the NKG2D-binding domains were

adsorbed, and cultured in the media containing fluorophore-conjugated anti-CD107a antibody, brefeldin-A, and monensin. Following culture in NKG2D-binding domain-coated wells, NK cells were assayed by flow cytometry using fluorophore-conjugated antibodies against CD3, NK1.1 and IFN-gamma. CD107a and IFN-gamma staining were analyzed in  
5 CD3<sup>-</sup> NK1.1<sup>+</sup> cells to assess NK cell activation. The increase in CD107a/IFN-gamma double-positive cells is indicative of better NK cell activation through engagement of two activating receptors rather than one receptor. NKG2D-binding domains and the positive control (selected from anti-mouse NKG2D clones MI-6 and CX-5 available at eBioscience) showed a higher percentage of NK cells becoming CD107a<sup>+</sup> and IFN-gamma<sup>+</sup> than the isotype control  
10 (FIG. 15 & FIG. 16 represent data from two independent experiments, each using a different mouse for NK cell preparation).

#### **Example 5 – NKG2D-binding domains enable cytotoxicity of target tumor cells**

**[00188]** Human and mouse primary NK cell activation assays demonstrate increased  
15 cytotoxicity markers on NK cells after incubation with NKG2D-binding domains. To address whether this translates into increased tumor cell lysis, a cell-based assay was utilized where each NKG2D-binding domain was developed into a monospecific antibody. The Fc region was used as one targeting arm, while the Fab region (NKG2D-binding domain) acted as another targeting arm to activate NK cells. THP-1 cells, which are of human origin and  
20 express high levels of Fc receptors, were used as a tumor target and a Perkin Elmer DELFIA Cytotoxicity Kit was used. THP-1 cells were labeled with BATDA reagent, and resuspended at 10<sup>5</sup>/mL in culture media. Labeled THP-1 cells were then combined with NKG2D antibodies and isolated mouse NK cells in wells of a microtiter plate at 37 °C for 3 hours. After incubation, 20 µl of the culture supernatant was removed, mixed with 200 µl of  
25 Europium solution and incubated with shaking for 15 minutes in the dark. Fluorescence was measured over time by a PheraStar plate reader equipped with a time-resolved fluorescence module (Excitation 337nm, Emission 620 nm) and specific lysis was calculated according to the kit instructions.

**[00189]** The positive control, ULBP-6 - a natural ligand for NKG2D, showed increased  
30 specific lysis of THP-1 target cells by mouse NK cells. NKG2D antibodies also increased specific lysis of THP-1 target cells, while isotype control antibody showed reduced specific lysis. The dotted line indicates specific lysis of THP-1 cells by mouse NK cells without antibody added (FIG. 17).

**Example 6 – NKG2D antibodies show high thermostability**

[00190] Melting temperatures of NKG2D-binding domains were assayed using differential scanning fluorimetry. The extrapolated apparent melting temperatures are high relative to typical IgG1 antibodies (FIG. 18).

5

**Example 7 - Synergistic activation of human NK cells by cross-linking NKG2D and CD16**Primary human NK cell activation assay

[00191] Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral  
10 human blood buffy coats using density gradient centrifugation. NK cells were purified from PBMCs using negative magnetic beads (StemCell # 17955). NK cells were >90% CD3<sup>-</sup>CD56<sup>+</sup> as determined by flow cytometry. Cells were then expanded 48 hours in media containing 100 ng/mL hIL-2 (Peprotech #200-02) before use in activation assays. Antibodies were coated onto a 96-well flat-bottom plate at a concentration of 2 µg/ml (anti-CD16, Biolegend # 302013) and 5 µg/mL (anti-NKG2D, R&D #MAB139) in 100 µl sterile PBS  
15 overnight at 4 °C followed by washing the wells thoroughly to remove excess antibody. For the assessment of degranulation IL-2-activated NK cells were resuspended at 5×10<sup>5</sup> cells/ml in culture media supplemented with 100 ng/mL hIL2 and 1 µg/mL APC-conjugated anti-CD107a mAb (Biolegend # 328619). 1×10<sup>5</sup> cells/well were then added onto antibody coated  
20 plates. The protein transport inhibitors Brefeldin A (BFA, Biolegend # 420601) and Monensin (Biolegend # 420701) were added at a final dilution of 1:1000 and 1:270 respectively. Plated cells were incubated for 4 hours at 37 °C in 5% CO<sub>2</sub>. For intracellular staining of IFN-γ NK cells were labeled with anti-CD3 (Biolegend #300452) and anti-CD56 mAb (Biolegend # 318328) and subsequently fixed and permeabilized and labeled with anti-  
25 IFN-γ mAb (Biolegend # 506507). NK cells were analyzed for expression of CD107a and IFN-γ by flow cytometry after gating on live CD56<sup>+</sup>CD3<sup>-</sup> cells.

[00192] To investigate the relative potency of receptor combination, crosslinking of NKG2D or CD16 and co-crosslinking of both receptors by plate-bound stimulation was performed. As shown in Figure 19 (FIGs. 19A-19C), combined stimulation of CD16 and  
30 NKG2D resulted in highly elevated levels of CD107a (degranulation) (FIG. 19A) and/or IFN-γ production (FIG. 19B). Dotted lines represent an additive effect of individual stimulations of each receptor.

[00193] CD107a levels and intracellular IFN-γ production of IL-2-activated NK cells were analyzed after 4 hours of plate-bound stimulation with anti-CD16, anti-NKG2D or a

combination of both monoclonal antibodies. Graphs indicate the mean ( $n = 2$ )  $\pm$  SD. FIG. 19A demonstrates levels of CD107a; FIG. 19B demonstrates levels of IFN $\gamma$ ; FIG. 19C demonstrates levels of CD107a and IFN $\gamma$ . Data shown in FIGs. 19A-19C are representative of five independent experiments using five different healthy donors.

5 **Example 8 – Multi-specific binding proteins bind to NKG2D**

[00194] EL4 mouse lymphoma cell lines were engineered to express human NKG2D. Trispecific binding proteins (TriNKETs) that each contain an NKG2D-binding domain, a tumor-associated antigen-binding domain (CD33-binding domain), and an Fc domain that binds to CD16 as shown in FIG. 1, were tested for their affinity to extracellular NKG2D  
10 expressed on EL4 cells. The binding of the multi-specific binding proteins to NKG2D was detected using fluorophore-conjugated anti-human IgG secondary antibodies. Cells were analyzed by flow cytometry, and fold-over-background (FOB) was calculated using the mean fluorescence intensity (MFI) of NKG2D-expressing cells compared to parental EL4 cells.

[00195] TriNKETs tested include CD33-TriNKET-C26 (ADI-28226 and a CD33-binding domain), CD33-TriNKET-F04 (ADI-29404 and a CD33-binding domain), CD33-TriNKET-A44 (ADI-27744 and a CD33-binding domain), CD33-TriNKET-F47 (ADI-29447 and a CD33-binding domain), CD33-TriNKET-A49 (ADI-27749 and a CD33-binding domain) and CD33-TriNKET-F63 (ADI-27463 and a CD33-binding domain). The CD33-binding domain used in the tested molecules was composed of a heavy chain variable domain and light chain  
20 variable domain as listed below.

CD33 heavy chain variable domain (SEQ ID NO:125):

QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYVVHWVWRQAPGQGLEWMGYINPY  
CDR1 (SEQ ID NO:127) CDR2

NDGTKYNEKFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYRYEVYGMDY  
25 (SEQ ID NO:128) CDR3 (SEQ ID NO:129)

WGQGTLVTVSS

CD33 light chain variable domain (SEQ ID NO:126):

DIVLTQSPASLAVSPGQRATITCTASSSVNYIHWYQQKPGQPPKLLIYDTSKVASGVP  
30 CDR1(SEQ ID NO:130) CDR2 (SEQ ID NO:131)

ARFSGSGSGTDFTLTINPVEANDTANYYCQQWRSYPLTFGQGTKLEIK  
CDR3 (SEQ ID NO:132)

[00196] The data show that TriNKETs which include a CD33-binding domain and a NKG2D-binding domain bind to NKG2D (FIGs. 35A-35B). FIG. 35A shows binding of the

TriNKETs in comparison with the monoclonal antibodies which contain the corresponding NKG2D binding domain. FIG. 35B shows the binding profile of CD33-targeting TriNKETs which include 6 different NKG2D binding domains.

### **Example 9 – Multi-specific binding proteins bind to human tumor antigens**

#### 5 Trispecific binding proteins bind to CD33

[00197] Human AML cell line MV4-11 and Molm-13 expressing CD33 were used to assay the binding of TriNKETs to the tumor associated antigen CD33. TriNKETs and optionally the parental anti-CD33 monoclonal antibody were incubated with the cells, and the binding was detected using fluorophore-conjugated anti-human IgG secondary antibodies.

10 Cells were analyzed by flow cytometry, and fold-over-background (FOB) was calculated using the mean fluorescence intensity (MFI) from the TriNKETs and the parental monoclonal anti-CD33 antibody normalized to secondary antibody controls. CD33-targeting TriNKETs show comparable levels of binding to CD33 as compared with the parental anti-CD33 antibody (FIG. 36). The TriNKETs show binding to cell surface CD33 on MV4-11 (FIG.

15 36A, 36B, and 36D) and Molm-13 cells (FIG. 36C). The overall binding signal is comparable among TriNKETs as they contain the same CD33 binding domain.

### **Example 10 – Multi-specific binding proteins activate NK cells**

[00198] Peripheral blood mononuclear cells (PBMCs) were isolated from human  
20 peripheral blood buffy coats using density gradient centrifugation. NK cells (CD3<sup>-</sup> CD56<sup>+</sup>) were isolated using negative selection with magnetic beads from PBMCs, and the purity of the isolated NK cells was typically >90%. Isolated NK cells were cultured in media containing 100 ng/mL IL-2 for activation or rested overnight without cytokine. IL-2-activated NK cells were used within 24-48 hours after activation.

25 [00199] MV4-11 cells expressing CD33 were harvested and resuspended in culture media at  $2 \times 10^6$ /mL. CD33 monoclonal antibodies or CD33-targeting TriNKETs were diluted in culture media. Activated NK cells were harvested, washed, and resuspended at  $2 \times 10^6$ /mL in culture media. Cancer cells were then mixed with monoclonal antibodies/TriNKETs and activated NK cells in the presence of IL-2. Brefeldin-A and monensin were also added to the  
30 mixed culture to block protein transport out of the cell for intracellular cytokine staining. Fluorophore-conjugated anti-CD107a was added to the mixed culture and the culture was incubated for 4 hours before samples were prepared for FACS analysis using fluorophore-

conjugated antibodies against CD3, CD56 and IFN-gamma. CD107a and IFN-gamma staining was analyzed in CD3<sup>-</sup> CD56<sup>+</sup> cells to assess NK cell activation. The increase in CD107a/IFN-gamma double-positive cells is indicative of better NK cell activation through engagement of two activating receptors rather than one receptor.

- 5 [00200] Co-culturing primary human NK cells with CD33-positive MV4-11 cells resulted in TriNKET-mediated activation of the primary human NK cells. A CD33 targeting TriNKET mediated activation of human NK cells co-cultured with MV4-11 cells, as indicated by an increase in CD107a degranulation and IFN $\gamma$  cytokine production (FIG. 37A and 37B). NK cells alone, NK cells co-culturing with MV4-11 cells but without TriNKETs, 10 CD20-targeting TriNKET were used as controls. Compared to the C33 monoclonal antibody, the CD33 targeting TriNKET showed increased NK cell activity (FIG. 37A and 37B).

#### **Example 11 – Trispecific binding proteins enable cytotoxicity of target cancer cells**

- [00201] Peripheral blood mononuclear cells (PBMCs) were isolated from human 15 peripheral blood buffy coats using density gradient centrifugation. NK cells (CD3<sup>-</sup> CD56<sup>+</sup>) were isolated using negative selection with magnetic beads from PBMCs, and the purity of the isolated NK cells was typically >90%. Isolated NK cells were cultured in media containing 100 ng/mL IL-2 for activation or rested overnight without cytokine. IL-2-activated or rested NK cells were used the following day in cytotoxicity assays.

#### 20 *DELFLIA cytotoxicity assay:*

- [00202] Human cancer cell lines expressing CD33 were harvested from culture, cells were washed with PBS, and were resuspended in growth media at 10<sup>6</sup>/mL for labeling with BATDA reagent (Perkin Elmer AD0116). Manufacturer instructions were followed for labeling of the target cells. After labeling cells were washed 3x with PBS, and were 25 resuspended at 0.5-1.0x10<sup>5</sup>/mL in culture media. To prepare the background wells an aliquot of the labeled cells was put aside, and the cells were spun out of the media. 100  $\mu$ l of the media was carefully added to wells in triplicate to avoid disturbing the pelleted cells. 100  $\mu$ l of BATDA labeled cells were added to each well of the 96-well plate. Wells were saved for spontaneous release from target cells, and wells were prepared for max lysis of target cells by 30 addition of 1% Triton-X. Monoclonal antibodies or TriNKETs against the tumor target of interest were diluted in culture media, 50  $\mu$ l of diluted mAb or TriNKET was added to each well. Rested and/or activated NK cells were harvested from culture, cells were washed, and were resuspended at 10<sup>5</sup>-2.0x10<sup>6</sup>/mL in culture media depending on the desired effector to

target cell ratio (E:T). 50 µl of NK cells was added to each well of the plate to make a total of 200 µl culture volume. The plate was incubated at 37 °C with 5% CO<sub>2</sub> for 2-3 hours before developing the assay.

[00203] After culturing for 2-3 hours, the plate was removed from the incubator and the  
5 cells were pelleted by centrifugation at 200g for 5 minutes. 20 µl of culture supernatant was transferred to a clean microplate provided from the manufacturer and 200 µl of room temperature europium solution was added to each well. The plate was protected from the light and incubated on a plate shaker at 250 rpm for 15 minutes. The plate was read using either Victor 3 or SpectraMax i3X instruments. % Specific lysis was calculated as follows: %  
10 Specific lysis = ((Experimental release – Spontaneous release) / (Maximum release – Spontaneous release)) \* 100%.

[00204] TriNKETs mediated cytotoxicity of human NK cells towards the CD33-positive human cancer cell lines. Rested human NK cells were mixed with MV4-11 cancer cells (FIG. 40A), rested human NK cells were mixed with Molm-13 cancer cells (FIG. 40B), and rested  
15 human NK cells were mixed with THP-1 cancer cells (FIG. 40C). TriNKETs (*e.g.*, CD33-TriNKET-C26 and CD33-TriNKET-F04) are able to enhance cytotoxic activity of rested human NK cells in a dose-responsive manner towards the cancer cells. The dotted line indicates cytotoxic activity of rested NK cells without the TriNKETs. CD33 monoclonal antibody showed reduced efficacy on MV4-11 cells, which express CD64, but at a lower  
20 level than THP-1 cells. CD33 monoclonal antibody showed good efficacy on Molm-13 cells, which do not express CD64. CD33 monoclonal antibody showed no effect on THP-1 cells, which have a high CD64 level.

[00205] TriNKET-mediated lysis of CD33-positive human cancer cells Molm-13 was assayed. Rested human NK cells were mixed with Molm-13 cancer cells at 5:1 ratio (FIG. 41), and TriNKETs (*e.g.*, CD33-TriNKET-A49, CD33-TriNKET-A44, CD33-TriNKET-C26,  
25 and CD33-TriNKET-E79) were able to enhance the cytotoxic activity of rested human NK cells in a dose-responsive manner towards the cancer cells. The dotted line indicates cytotoxic activity of rested NK cells without TriNKETs.

### 30 **Example 12 – The advantage of TriNKETs in treating cancers with high expression of FcR, or in tumor microenvironments with high levels of FcR**

[00206] Monoclonal antibody therapy has been approved for the treatment of many cancer types, including both hematological and solid tumors. While the use of monoclonal antibodies in cancer treatment has improved patient outcomes, there are still limitations.



Mechanistic studies have demonstrated monoclonal antibodies exert their effects on tumor growth through multiple mechanisms including ADCC, CDC, phagocytosis, and signal blockade amongst others.

[00207] Most notably, ADCC is thought to be a major mechanism through which  
5 monoclonal antibodies exert their effect. ADCC relies on antibody Fc engagement of the low-affinity Fc $\gamma$ RIII (CD16) on the surface of natural killer cells, which mediate direct lysis of the tumor cell. Amongst Fc $\gamma$ R, CD16 has the lowest affinity for IgG Fc, Fc $\gamma$ RI (CD64) is the high-affinity FcR, and binds about 1000 times stronger to IgG Fc than CD16.

[00208] CD64 is normally expressed on many hematopoietic lineages such as the myeloid  
10 lineage, and can be expressed on tumors derived from these cell types, such as acute myeloid leukemia (AML). Immune cells infiltrating into the tumor, such as MDSCs and monocytes, also express CD64 and are known to infiltrate the tumor microenvironment. Expression of CD64 by the tumor or in the tumor microenvironment can have a detrimental effect on monoclonal antibody therapy. Expression of CD64 in the tumor microenvironment makes it  
15 difficult for these antibodies to engage CD16 on the surface of NK cells, as the antibodies prefer to bind the high-affinity receptor. Through targeting two activating receptors on the surface of NK cells, TriNKETs may be able to overcome the detrimental effect of CD64 expression on monoclonal antibody therapy.

#### **FcR $\gamma$ I (CD64) expression on three AML cell lines**

[00209] An *in vitro* culture system was developed to test the activity of TriNKETs and  
20 monoclonal antibodies against tumors with high and low levels of CD64 surface expression. Molm-13 and THP-1 are two human AML cell lines which have similar expression of surface CD33, but Molm-13 cells do not express CD64, while THP-1 cells express CD64 on their surface (FIGs. 38A – 38C). Using monoclonal antibodies or TriNKETs directed to target  
25 CD33, the effect of CD64 expression by the tumor on monoclonal antibody or TriNKET therapy was tested. FIGs. 38A – 38C showed the expression of the high-affinity FcR $\gamma$ I (CD64) on three human AML cells lines, Molm-13 cell line (FIG. 38A), MV4-11 cell line (FIG. 38B), and THP-1 cell line (FIG. 38C). Molm-13 cells do not express CD64, while MV4-11 cells have a low level, and THP-1 have a high level of cell surface CD64.

30

**TriNKETs have an advantage in targeting tumor cells with high surface expression of FcRs**

[00210] FIGs. 39A – 39B show monoclonal antibody or TriNKET mediated activation of human NK cells in co-culture with either Molm-13 (FIG. 39B) or THP-1 (FIG. 39A) cells. A  
5 monoclonal antibody against human CD33 demonstrated good activation of human NK cells, in the Molm-13 co-culture system as evidenced by increased CD107a degranulation and IFN $\gamma$  production. The monoclonal antibody has no effect on the THP-1 co-culture system, where high levels of CD64 are present on the cancer cells. Interestingly, TriNKETs are effective against both Molm-13 (FIG. 39B) and THP-1 (FIG. 39A) cells, indicating that TriNKETs are  
10 able to overcome binding to CD64 on the tumor, and effectively target NK cells for activation. Dual targeting of two activating receptors on NK cells provided stronger specific binding to NK cells. Monoclonal antibodies, which only target CD16 on NK cells, can be bound by other high-affinity FcRs, and prevent engagement of CD16 on NK cells. As show in FIG. 39C, TriNKETs also efficiently mediated activation of rested human NK cells in co-  
15 culture with MV4-11 human AML cells.

**TriNKETs demonstrate efficacy on AML cell lines regardless of Fc $\gamma$ RI expression**

[00211] FIGs. 40A – 40C show human NK cytotoxicity assays using the three human AML cell lines as targets. A monoclonal antibody against CD33 showed good efficacy against Molm-13 cells (FIG. 40B), which do not express CD64. MV4-11 cells (FIG. 40A),  
20 which express CD64, but at a lower level than THP-1, showed reduced efficacy with the monoclonal anti-CD33. THP-1 cells (FIG. 40C) showed no effect with monoclonal anti-CD33 alone. Regardless of CD64 expression on the tumor cells, TriNKETs were able to mediate human NK cell responses against all tumor cells tested here.

[00212] FIGs. 40A – 40C show that THP-1 cells were protected against monoclonal  
25 antibody therapy, due to high levels of high-affinity FcR expression on their surface. TriNKETs circumvented this protection by targeting two activating receptors on the surface of NK cells. Cytotoxicity data correlated directly to what was seen in the co-culture activation experiments. TriNKETs were able to circumvent protection from mAb therapy seen with THP-1 cells, and induce NK cell mediated lysis despite high levels of FcR.

30 **Example 13 - Killing of normal myeloid and normal B cells in PBMC cultures:  
TriNKETs provide better safety profile through less on-target off-tumor side effects**

[00213] Natural killer cells and CD8 T cells are both able to directly lyse tumor cells, although the mechanisms through which NK cells and CD8 T cells recognize normal self from tumor cells differ. The activity of NK cells is regulated by the balance of signals from activating (NCRs, NKG2D, CD16, *etc.*) and inhibitory (KIRs, NKG2A, *etc.*) receptors. The  
5 balance of these activating and inhibitory signals allow NK cells to determine healthy self-cells from stressed, virally infected, or transformed self-cells. This “built-in” mechanism of self-tolerance, will help protect normal healthy tissue from NK cell responses. To extend this principle, the self-tolerance of NK cells will allow TriNKETs to target antigens expressed both on self and tumor without off tumor side effects, or with an increased therapeutic  
10 window.

[00214] Unlike natural killer cells, T cells require recognition of a specific peptide presented by MHC molecules for activation and effector functions. T cells have been the primary target of immunotherapy, and many strategies have been developed to redirect T cell responses against the tumor. T cell bispecifics, checkpoint inhibitors, and CAR-T cells have  
15 all been approved by the FDA, but often suffer from dose-limiting toxicities. T cell bispecifics and CAR-T cells work around the TCR-MHC recognition system by using binding domains to target antigens on the surface of tumor cells, and using engineered signaling domains to transduce the activation signals into the effector cell. Although effective at eliciting an anti-tumor immune response these therapies are often coupled with  
20 cytokine release syndrome (CRS), and on-target off-tumor side effects. TriNKETs are unique in this context as they will not “override” the natural systems of NK cell activation and inhibition. Instead, TriNKETs are designed to sway the balance, and provide additional activation signals to the NK cells, while maintaining NK tolerance to healthy self.

[00215] PBMCs were isolated from whole blood by density gradient centrifugation. Any  
25 contaminating red blood cells were lysed by incubation in ACK lysis buffer. PBMCs were washed 3x in PBS, and total PBMCs were counted. PBMCs were adjusted to  $10^6$ /mL in primary cell culture media. 1mL of PBMCs were seeded into wells of a 24 well plate, the indicated TriNKETs or mAbs were added to the PBMC cultures at 10  $\mu$ g/mL. Cells were cultured overnight at 37°C with 5% CO<sub>2</sub>. The following day (24 hours later) PBMCs were  
30 harvested from culture and prepared for FACS analysis. The percentage of CD45+; CD19+ B cells and CD45+; CD33+; CD11b+ myeloid cells was analyzed over the different treatment groups.

[00216] FIG. 42A shows that B cells (CD33-negative) from a healthy donor were unaffected by CD33-targeting TriNKET. PBMCs treated with TriNKETs-targeting CD33

showed no effect on CD45+, CD3-, CD56- lymphocyte population. FIG. 42B shows that autologous CD33+ myeloid cells were protected from CD33-targeting TriNKET-mediated NK cell responses, and, therefore, were resistant to TriNKET-mediated lysis. In these cultures, the frequency of CD45+, CD33+, CD11b+ myeloid cells were unchanged upon  
5 incubation with CD33-targeting TriNKETs.

#### INCORPORATION BY REFERENCE

[00217] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.

10

#### EQUIVALENTS

[00218] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing  
15 description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

CLAIMS

## WHAT IS CLAIMED IS:

1. A protein comprising:
  - (a) a first antigen-binding site that binds NKG2D;
  - (b) a second antigen-binding site that binds CD33; and
  - (c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16.
2. The protein of claim 1, wherein the first antigen-binding site binds to NKG2D in humans, non-human primates, and rodents.
3. The protein of claim 1 or 2, wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.
4. A protein according to claim 3, wherein the heavy chain variable domain and the light chain variable domain are present on the same polypeptide.
5. The protein according to any one of claims 3-4, wherein the second antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.
6. The protein according to claim 5, wherein the heavy chain variable domain and the light chain variable domain of the second antigen-binding site are present on the same polypeptide.
7. The protein according to claim 5 or 6, wherein the light chain variable domain of the first antigen-binding site has an amino acid sequence identical to the amino acid sequence of the light chain variable domain of the second antigen-binding site.
8. The protein according to any one of the preceding claims, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:1.
9. The protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:41 and a light chain variable domain at least 90% identical to SEQ ID NO:42.

10. The protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:43 and a light chain variable domain at least 90% identical to SEQ ID NO:44.
11. The protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:45 and a light chain variable domain at least 90% identical to SEQ ID NO:46.
12. The protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:47 and a light chain variable domain at least 90% identical to SEQ ID NO:48.
13. The protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:69 and a light chain variable domain at least 90% identical to SEQ ID NO:70.
14. The protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:77 and a light chain variable domain at least 90% identical to SEQ ID NO:78.
15. The protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:85 and a light chain variable domain at least 90% identical to SEQ ID NO:86.
16. The protein according to any of claims 1-7, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:133 and a light chain variable domain at least 90% identical to SEQ ID NO:134.
17. The protein of claim 1 or 2, wherein the first antigen-binding site is a single-domain antibody.
18. The protein of claim 17, wherein the single-domain antibody is a V<sub>H</sub>H fragment or a V<sub>NAR</sub> fragment.
19. The protein according to any one of claims 1-2 or 17-18, wherein the second antigen-binding site comprises a heavy chain variable domain and a light chain variable domain.

20. The protein according to claim 19, wherein the heavy chain variable domain and the light chain variable domain of the second antigen-binding site are present on the same polypeptide.
21. A protein according to any of the preceding claims, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:93 and the light chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:94.
22. A protein according to any one of claims 1-20, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:101 and the light chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:102.
23. A protein according to any one of claims 1-20, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:109 and the light chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:110.
24. A protein according to any one of claims 1-20, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:117 and the light chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:118.
25. A protein according to any one of claims 1-20, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:125 and the light chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:126.
26. The protein according to any one of claims 1-4 or 8-16, wherein the second antigen-binding site is a single-domain antibody.
27. The protein of claim 26, wherein the second antigen-binding site is a V<sub>H</sub>H fragment or a V<sub>NAR</sub> fragment.

28. A protein according to any one of the preceding claims, wherein the protein comprises a portion of an antibody Fc domain sufficient to bind CD16, wherein the antibody Fc domain comprises hinge and CH2 domains.
29. The protein according to claim 28, wherein the antibody Fc domain comprises hinge and CH2 domains of a human IgG1 antibody.
30. The protein according to claim 28 or 29, wherein the Fc domain comprises an amino acid sequence at least 90% identical to amino acids 234-332 of a human IgG1 antibody.
31. The protein according to any one of claims 28-30, wherein the Fc domain comprises amino acid sequence at least 90% identical to the Fc domain of human IgG1 and differs at one or more positions selected from the group consisting of Q347, Y349, T350, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411, K439.
32. A formulation comprising a protein according to any one of the preceding claims and a pharmaceutically acceptable carrier.
33. A cell comprising one or more nucleic acids expressing a protein according to any one of claims 1-31.
34. A method of directly and/or indirectly enhancing tumor cell death, the method comprising exposing a tumor and natural killer cells to a protein according to any one of claims 1-31.
35. A method of treating cancer, wherein the method comprises administering a protein according to any one of claims 1-31 or a formulation according to claim 32 to a patient.
36. The method of claim 35, wherein the cancer is selected from the group consisting of AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, and ALLs.



FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16






FIG. 17




FIG. 18




FIG. 19A




FIG. 19B




FIG. 19C




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30A




FIG. 30B




FIG. 31




FIG. 32






FIG. 33




FIG. 34




FIG. 35A




FIG. 35B




FIG. 36A




FIG. 36B




FIG. 36C




FIG. 36D




FIG. 37A




FIG. 37B




FIG. 38A

FIG. 38B

FIG. 38C




FIG. 39A




FIG. 39B




FIG. 39C




FIG. 40A




FIG. 40B






FIG. 40C




FIG. 41




FIG. 42A





FIG. 42B



DFY-007PC\_SL.TXT  
SEQUENCE LISTING

<110> ADIMAB, LLC.

<120> PROTEINS BINDING CD33, NKG2D AND CD16

<130> DFY-007PC

<140>

<141>

<150> 62/461,145

<151> 2017-02-20

<160> 140

<170> PatentIn version 3.5

<210> 1

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 1

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

DFY-007PC\_SL.TXT

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 2

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 2

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Ile  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 3

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 3

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 4

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 4

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser  
20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu  
 35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser  
 50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu  
 65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro  
 85 90 95

Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 5

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 5

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
 20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
 35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
 65 70 75 80

DFY-007PC\_SL.TXT

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 6

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 6

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Phe Tyr Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 7

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 7

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
 20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
 35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
 100 105 110

Val Thr Val Ser Ser  
 115

<210> 8

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 8

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
 1 5 10 15



DFY-007PC\_SL.TXT

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Ser Tyr Tyr Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 9

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 9

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

DFY-007PC\_SL.TXT

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 10  
<211> 106  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 10  
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 11  
<211> 117  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 11  
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 12  
<211> 107  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

DFY-007PC\_SL.TXT

<400> 12

Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Gln Ser Ile Ser Ser Tyr  
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile  
35 40 45

Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Asp Ile Pro Tyr  
85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 13

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 13

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

DFY-007PC\_SL.TXT

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 14

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 14

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Ser Phe Pro Ile  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 15  
<211> 117  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 15  
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 16  
<211> 107  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 16

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Lys Glu Val Pro Trp  
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 17

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 17

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

DFY-007PC\_SL.TXT

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 18

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 18

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80



Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Phe Pro Thr  
 85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 19  
 <211> 117  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 19  
 Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
 20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
 35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
 100 105 110

Val Thr Val Ser Ser  
 115

<210> 20  
<211> 106  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 20  
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Ile Tyr Pro Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 21  
<211> 117  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 21  
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

DFY-007PC\_SL.TXT

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 22  
<211> 106  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 22  
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

DFY-007PC\_SL.TXT

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Ser Tyr Pro Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 23

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 23

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 24  
<211> 106  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 24  
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Ser Phe Pro Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 25  
<211> 117  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 25

DFY-007PC\_SL.TXT

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 26

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 26

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
 65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Gln Ser Phe Pro Thr  
 85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 27

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 27

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
 20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
 35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95

DFY-007PC\_SL.TXT

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 28  
<211> 106  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 28  
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Ser Phe Ser Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 29  
<211> 117  
<212> PRT  
<213> Artificial Sequence

<220>



<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 29

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
 20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
 35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
 100 105 110

Val Thr Val Ser Ser  
 115

<210> 30

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 30

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Glu Ser Tyr Ser Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 31

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 31

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

DFY-007PC\_SL.TXT

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 32

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 32

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Ser Phe Ile Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 33

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 33

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 34

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 34

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

DFY-007PC\_SL.TXT

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Gln Ser Tyr Pro Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 35

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 35

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

DFY-007PC\_SL.TXT

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

- <210> 36
- <211> 106
- <212> PRT
- <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 36  
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Phe Pro Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 37  
<211> 117  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 37  
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 38  
<211> 107  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

DFY-007PC\_SL.TXT

<400> 38

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Glu Leu Tyr Ser Tyr  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 39

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 39

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45



DFY-007PC\_SL.TXT

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 40

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 40

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Thr Phe Ile Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 41  
<211> 125  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 41  
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr  
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Gly Asp Ser Ser Ile Arg His Ala Tyr Tyr Tyr Tyr Gly Met  
100 105 110

Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
115 120 125

<210> 42  
<211> 113  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 42

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly  
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser  
20 25 30

Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln  
35 40 45

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val  
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr  
65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln  
85 90 95

Tyr Tyr Ser Thr Pro Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile  
100 105 110

Lys

<210> 43

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 43

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu  
1 5 10 15

DFY-007PC\_SL.TXT

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser  
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu  
35 40 45

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser  
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe  
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr  
85 90 95

Cys Ala Arg Gly Ser Asp Arg Phe His Pro Tyr Phe Asp Tyr Trp Gly  
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 44

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 44

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Asp Thr Trp Pro Pro  
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 100 105

<210> 45

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 polypeptide

<400> 45

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu  
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr  
 20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
 35 40 45

Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys  
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
 85 90 95

Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu  
 100 105 110

Val Thr Val Ser Ser  
115

<210> 46  
<211> 106  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 46  
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Glu Gln Tyr Asp Ser Tyr Pro Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 47  
<211> 126  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 47

DFY-007PC\_SL.TXT

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr  
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Arg Gly Arg Lys Ala Ser Gly Ser Phe Tyr Tyr Tyr Tyr Gly  
100 105 110

Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
115 120 125

<210> 48

<211> 113

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 48

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly  
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Glu Ser Ser Gln Ser Leu Leu Asn Ser  
20 25 30

Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln  
35 40 45

DFY-007PC\_SL.TXT

Pro Pro Lys Pro Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val  
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr  
65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn  
85 90 95

Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile  
100 105 110

Lys

<210> 49

<211> 121

<212> PRT

<213> Homo sapiens

<400> 49

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95



DFY-007PC\_SL.TXT

Ala Lys Asp Arg Gly Leu Gly Asp Gly Thr Tyr Phe Asp Tyr Trp Gly  
100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser  
115 120

<210> 50  
<211> 110  
<212> PRT  
<213> Homo sapiens

<400> 50  
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln  
1 5 10 15

Ser Ile Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn  
20 25 30

Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu  
35 40 45

Ile Tyr Tyr Asp Asp Leu Leu Pro Ser Gly Val Ser Asp Arg Phe Ser  
50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Phe Leu Ala Ile Ser Gly Leu Gln  
65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu  
85 90 95

Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu  
100 105 110

<210> 51  
<211> 115  
<212> PRT  
<213> Homo sapiens

<400> 51  
Gln Val His Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu  
1 5 10 15

DFY-007PC\_SL.TXT

Thr Leu Ser Leu Thr Cys Thr Val Ser Asp Asp Ser Ile Ser Ser Tyr  
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile  
35 40 45

Gly His Ile Ser Tyr Ser Gly Ser Ala Asn Tyr Asn Pro Ser Leu Lys  
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu  
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala  
85 90 95

Asn Trp Asp Asp Ala Phe Asn Ile Trp Gly Gln Gly Thr Met Val Thr  
100 105 110

Val Ser Ser  
115

<210> 52  
<211> 108  
<212> PRT  
<213> Homo sapiens

<400> 52  
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser  
20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu  
35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser  
50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu  
65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro  
                   85                                  90                                  95

Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
                   100                                  105

<210> 53  
 <211> 364  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
           polypeptide

<400> 53  
 Met Pro Leu Leu Leu Leu Leu Pro Leu Leu Trp Ala Gly Ala Leu Ala  
 1                  5                                  10                                  15

Met Asp Pro Asn Phe Trp Leu Gln Val Gln Glu Ser Val Thr Val Gln  
                   20                                  25                                  30

Glu Gly Leu Cys Val Leu Val Pro Cys Thr Phe Phe His Pro Ile Pro  
                   35                                  40                                  45

Tyr Tyr Asp Lys Asn Ser Pro Val His Gly Tyr Trp Phe Arg Glu Gly  
                   50                                  55                                  60

Ala Ile Ile Ser Arg Asp Ser Pro Val Ala Thr Asn Lys Leu Asp Gln  
                   65                                  70                                  75                                  80

Glu Val Gln Glu Glu Thr Gln Gly Arg Phe Arg Leu Leu Gly Asp Pro  
                   85                                  90                                  95

Ser Arg Asn Asn Cys Ser Leu Ser Ile Val Asp Ala Arg Arg Arg Asp  
                   100                                  105                                  110

Asn Gly Ser Tyr Phe Phe Arg Met Glu Arg Gly Ser Thr Lys Tyr Ser  
                   115                                  120                                  125

DFY-007PC\_SL.TXT

Tyr Lys Ser Pro Gln Leu Ser Val His Val Thr Asp Leu Thr His Arg  
 130 135 140

Pro Lys Ile Leu Ile Pro Gly Thr Leu Glu Pro Gly His Ser Lys Asn  
 145 150 155 160

Leu Thr Cys Ser Val Ser Trp Ala Cys Glu Gln Gly Thr Pro Pro Ile  
 165 170 175

Phe Ser Trp Leu Ser Ala Ala Pro Thr Ser Leu Gly Pro Arg Thr Thr  
 180 185 190

His Ser Ser Val Leu Ile Ile Thr Pro Arg Pro Gln Asp His Gly Thr  
 195 200 205

Asn Leu Thr Cys Gln Val Lys Phe Ala Gly Ala Gly Val Thr Thr Glu  
 210 215 220

Arg Thr Ile Gln Leu Asn Val Thr Tyr Val Pro Gln Asn Pro Thr Thr  
 225 230 235 240

Gly Ile Phe Pro Gly Asp Gly Ser Gly Lys Gln Glu Thr Arg Ala Gly  
 245 250 255

Val Val His Gly Ala Ile Gly Gly Ala Gly Val Thr Ala Leu Leu Ala  
 260 265 270

Leu Cys Leu Cys Leu Ile Phe Phe Ile Val Lys Thr His Arg Arg Lys  
 275 280 285

Ala Ala Arg Thr Ala Val Gly Arg Asn Asp Thr His Pro Thr Thr Gly  
 290 295 300

Ser Ala Ser Pro Lys His Gln Lys Lys Ser Lys Leu His Gly Pro Thr  
 305 310 315 320

Glu Thr Ser Ser Cys Ser Gly Ala Ala Pro Thr Val Glu Met Asp Glu  
 325 330 335

DFY-007PC\_SL.TXT

Glu Leu His Tyr Ala Ser Leu Asn Phe His Gly Met Asn Pro Ser Lys  
340 345 350

Asp Thr Ser Thr Glu Tyr Ser Glu Val Arg Thr Gln  
355 360

<210> 54

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 54

Gly Ser Phe Ser Gly Tyr Tyr Trp Ser  
1 5

<210> 55

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 55

Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser  
1 5 10 15

<210> 56

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 56

Ala Arg Ala Arg Gly Pro Trp Ser Phe Asp Pro  
1 5 10

<210> 57

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 57

Gly Thr Phe Ser Ser Tyr Ala Ile Ser  
1 5

<210> 58

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 58

Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln  
1 5 10 15

Gly

<210> 59

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 59

Ala Arg Gly Asp Ser Ser Ile Arg His Ala Tyr Tyr Tyr Tyr Gly Met  
1 5 10 15

Asp Val

<210> 60

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 60

Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu  
1                   5                   10                   15

Ala

<210> 61

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 61

Trp Ala Ser Thr Arg Glu Ser  
1                   5

<210> 62

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 62

Gln Gln Tyr Tyr Ser Thr Pro Ile Thr  
1                   5

<210> 63

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 63

Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly  
1 5 10

<210> 64  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 64  
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser  
1 5 10 15

<210> 65  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 65  
Ala Arg Gly Ser Asp Arg Phe His Pro Tyr Phe Asp Tyr  
1 5 10

<210> 66  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 66  
Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu Ala  
1 5 10

<210> 67  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>



<223> Description of Artificial Sequence: Synthetic peptide

<400> 67

Asp Ala Ser Asn Arg Ala Thr  
1 5

<210> 68

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 68

Gln Gln Phe Asp Thr Trp Pro Pro Thr  
1 5

<210> 69

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 69

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80

DFY-007PC\_SL.TXT

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Lys Asp Gly Gly Tyr Tyr Asp Ser Gly Ala Gly Asp Tyr Trp Gly  
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 70

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 70

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asp Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Val Ser Tyr Pro Arg  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 71

<211> 9

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 71  
Phe Thr Phe Ser Ser Tyr Ala Met Ser  
1 5

<210> 72  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 72  
Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 73  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 73  
Ala Lys Asp Gly Gly Tyr Tyr Asp Ser Gly Ala Gly Asp Tyr  
1 5 10

<210> 74  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 74

Arg Ala Ser Gln Gly Ile Asp Ser Trp Leu Ala  
1 5 10

<210> 75

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 75

Ala Ala Ser Ser Leu Gln Ser  
1 5

<210> 76

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 76

Gln Gln Gly Val Ser Tyr Pro Arg Thr  
1 5

<210> 77

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 77

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30

DFY-007PC\_SL.TXT

Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Gly Ala Pro Met Gly Ala Ala Ala Gly Trp Phe Asp Pro Trp  
100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 78

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 78

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp  
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Val Ser Phe Pro Arg  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 79  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 79  
Phe Thr Phe Ser Ser Tyr Ser Met Asn  
1 5

<210> 80  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 80  
Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 81  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 81

DFY-007PC\_SL.TXT

Ala Arg Gly Ala Pro Met Gly Ala Ala Ala Gly Trp Phe Asp Pro  
1 5 10 15

<210> 82

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 82

Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala  
1 5 10

<210> 83

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 83

Ala Ala Ser Ser Leu Gln Ser  
1 5

<210> 84

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 84

Gln Gln Gly Val Ser Phe Pro Arg Thr  
1 5

<210> 85

<211> 124

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 85

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr  
 20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
 50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr  
 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg Asp Thr Gly Glu Tyr Tyr Asp Thr Asp Asp His Gly Met Asp  
 100 105 110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
 115 120

<210> 86

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 86

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly  
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn  
 20 25 30



Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asp Asp Tyr Trp Pro Pro  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
100 105

<210> 87  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 87  
Tyr Thr Phe Thr Gly Tyr Tyr Met His  
1 5

<210> 88  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 88  
Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln  
1 5 10 15

Gly

<210> 89  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 89  
Ala Arg Asp Thr Gly Glu Tyr Tyr Asp Thr Asp Asp His Gly Met Asp  
1                   5                   10                   15

Val

<210> 90  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 90  
Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala  
1                   5                   10

<210> 91  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 91  
Gly Ala Ser Thr Arg Ala Thr  
1                   5

<210> 92  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 92

Gln Gln Asp Asp Tyr Trp Pro Pro Thr  
 1 5

<210> 93

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 93

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr  
 20 25 30

Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile  
 35 40 45

Gly Tyr Ile Tyr Pro Tyr Asn Gly Gly Thr Gly Tyr Asn Gln Lys Phe  
 50 55 60

Lys Ser Lys Ala Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr  
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg Gly Arg Pro Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val  
 100 105 110

Thr Val Ser Ser  
 115

<210> 94

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 94

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr  
 20 25 30

Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro  
 35 40 45

Lys Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ser  
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser  
 65 70 75 80

Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Lys  
 85 90 95

Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 100 105 110

<210> 95

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 95

Gly Tyr Thr Phe Thr Asp Tyr  
 1 5

<210> 96

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 96

Tyr Ile Tyr Pro Tyr Asn Gly Gly Thr Gly  
1                    5                    10

<210> 97

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 97

Gly Arg Pro Ala Met Asp Tyr  
1                    5

<210> 98

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 98

Glu Ser Val Asp Asn Tyr Gly Ile Ser Phe Met Asn  
1                    5                    10

<210> 99

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 99

Ala Ala Ser Asn Gln Gly Ser  
1 5

<210> 100  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 100  
Gln Gln Ser Lys Glu Val Pro Trp Thr  
1 5

<210> 101  
<211> 116  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 101  
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Ile Thr Asp Ser  
20 25 30

Asn Ile His Trp Val Arg Gln Ala Pro Gly Gln Ser Leu Glu Trp Ile  
35 40 45

Gly Tyr Ile Tyr Pro Tyr Asn Gly Gly Thr Asp Tyr Asn Gln Lys Phe  
50 55 60

Lys Asn Arg Ala Thr Leu Thr Val Asp Asn Pro Thr Asn Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Phe Tyr Tyr Cys  
85 90 95

DFY-007PC\_SL.TXT

Val Asn Gly Asn Pro Trp Leu Ala Tyr Trp Gly Gln Gly Thr Leu Val  
100 105 110

Thr Val Ser Ser  
115

<210> 102  
<211> 111  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
polypeptide

<400> 102  
Asp Ile Gln Leu Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Leu Asp Asn Tyr  
20 25 30

Gly Ile Arg Phe Leu Thr Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro  
35 40 45

Lys Leu Leu Met Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ser  
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser  
65 70 75 80

Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Lys  
85 90 95

Glu Val Pro Trp Ser Phe Gly Gln Gly Thr Lys Val Glu Val Lys  
100 105 110

<210> 103  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 103

Gly Tyr Thr Ile Thr Asp Ser  
1 5

<210> 104

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 104

Tyr Ile Tyr Pro Tyr Asn Gly Gly Thr Asp  
1 5 10

<210> 105

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 105

Gly Asn Pro Trp Leu Ala Tyr  
1 5

<210> 106

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 106

Glu Ser Leu Asp Asn Tyr Gly Ile Arg Phe Leu Thr  
1 5 10

<210> 107

<211> 7



<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 107

Ala Ala Ser Asn Gln Gly Ser  
1 5

<210> 108

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 108

Gln Gln Thr Lys Glu Val Pro Trp Ser  
1 5

<210> 109

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 109

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Val Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Tyr Ile His Trp Ile Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Val  
35 40 45

Gly Val Ile Tyr Pro Gly Asn Asp Asp Ile Ser Tyr Asn Gln Lys Phe  
50 55 60

DFY-007PC\_SL.TXT

Gln Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Glu Val Arg Leu Arg Tyr Phe Asp Val Trp Gly Gln Gly Thr  
100 105 110

Thr Val Thr Val Ser Ser  
115

- <210> 110
- <211> 113
- <212> PRT
- <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 110  
Glu Ile Val Leu Thr Gln Ser Pro Gly Ser Leu Ala Val Ser Pro Gly  
1 5 10 15

Glu Arg Val Thr Met Ser Cys Lys Ser Ser Gln Ser Val Phe Phe Ser  
20 25 30

Ser Ser Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Ile Pro Gly Gln  
35 40 45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val  
50 55 60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr  
65 70 75 80

Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Ile Tyr Tyr Cys His Gln  
85 90 95

Tyr Leu Ser Ser Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys  
100 105 110

Arg

<210> 111  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 111  
Gly Tyr Thr Phe Thr Ser Tyr  
1 5

<210> 112  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 112  
Tyr Pro Gly Asn Asp Asp  
1 5

<210> 113  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 113  
Glu Val Arg Leu Arg Tyr Phe Asp Val  
1 5

<210> 114  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 114

Gln Ser Val Phe Phe Ser Ser Ser Gln Lys Asn Tyr Leu Ala  
1 5 10

<210> 115

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 115

Trp Ala Ser Thr Arg Glu Ser  
1 5

<210> 116

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 116

His Gln Tyr Leu Ser Ser Arg Thr  
1 5

<210> 117

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 117

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

DFY-007PC\_SL.TXT

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Trp Ile Tyr Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe  
50 55 60

Lys Ala Lys Ala Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr  
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Ser Gly Tyr Glu Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr  
100 105 110

Val Thr Val Ser Ser Ala  
115

<210> 118

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 118

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr  
20 25 30

Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Thr Leu Ile  
35 40 45

Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Gln Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Leu  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg  
100 105

<210> 119  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 119  
Gly Tyr Thr Phe Thr Asn Tyr  
1 5

<210> 120  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 120  
Tyr Pro Gly Asp Gly Ser  
1 5

<210> 121  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 121

Gly Tyr Glu Asp Ala Met Asp Tyr  
1 5

<210> 122  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 122  
Gln Asp Ile Asn Ser Tyr Leu Ser  
1 5

<210> 123  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 123  
Arg Ala Asn Arg Leu Val Asp  
1 5

<210> 124  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 124  
Leu Gln Tyr Asp Glu Phe Pro Leu Thr  
1 5

<210> 125  
<211> 120  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 125

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr  
 20 25 30

Val Val His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45

Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe  
 50 55 60

Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr  
 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Arg Asp Tyr Arg Tyr Glu Val Tyr Gly Met Asp Tyr Trp Gly Gln  
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 126

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 126

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly  
 1 5 10 15

Gln Arg Ala Thr Ile Thr Cys Thr Ala Ser Ser Ser Val Asn Tyr Ile  
 20 25 30



His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr  
35 40 45

Asp Thr Ser Lys Val Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn  
65 70 75 80

Asp Thr Ala Asn Tyr Tyr Cys Gln Gln Trp Arg Ser Tyr Pro Leu Thr  
85 90 95

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 127  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 127  
Asp Tyr Val Val His  
1 5

<210> 128  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 128  
Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys  
1 5 10 15

Gly

<210> 129  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 129  
Asp Tyr Arg Tyr Glu Val Tyr Gly Met Asp Tyr  
1 5 10

<210> 130  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 130  
Thr Ala Ser Ser Ser Val Asn Tyr Ile His  
1 5 10

<210> 131  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 131  
Asp Thr Ser Lys Val Ala Ser  
1 5

<210> 132  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 132

Gln Gln Trp Arg Ser Tyr Pro Leu Thr  
1 5

<210> 133

<211> 126

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 133

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Gly Ala Pro Asn Tyr Gly Asp Thr Thr His Asp Tyr Tyr Tyr  
100 105 110

Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser  
115 120 125

<210> 134

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 134

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly  
 1                   5                   10                   15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn  
           20                   25                   30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
       35                   40                   45

Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
       50                   55                   60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser  
 65                   70                   75                   80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Asp Trp Pro Phe  
           85                   90                   95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
           100                   105

<210> 135

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 135

Tyr Thr Phe Thr Ser Tyr Tyr Met His  
 1                   5

<210> 136

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 136

Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln  
1                   5                   10                   15

Gly

<210> 137

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 137

Ala Arg Gly Ala Pro Asn Tyr Gly Asp Thr Thr His Asp Tyr Tyr Tyr  
1                   5                   10                   15

Met Asp Val

<210> 138

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 138

Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala  
1                   5                   10

<210> 139

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

DFY-007PC\_SL.TXT

<223> Description of Artificial Sequence: Synthetic peptide

<400> 139

Gly Ala Ser Thr Arg Ala Thr  
1 5

<210> 140

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 140

Gln Gln Tyr Asp Asp Trp Pro Phe Thr  
1 5